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Biopharmaceuticals are a burgeoning class of therapeutics that are revolutionizing the way 
disease is treated. Despite their considerable success, the ability to control glycosylation—a key 
design parameter that ensures safety, optimizes biological response, and influences the 
pharmacokinetic properties of biopharmaceuticals—has been elusive, which has slowed the 
development of this class of drugs. One specific glycan, sialic acid, has received considerable attention 
due to its role in the efficacy, pharmacodynamic, and pharmacokinetic properties of 
biopharmaceuticals. The first part of this project used a combined genetic and metabolic engineering 
strategy to gain enhanced exogenous control over the magnitude and type of sialyation produced by 
Chinese hamster ovary (CHO) cells. In order to significantly reduce endogenous flux of ManNAc into 
the sialic acid biosynthetic pathway (SABP) two key enzymes in this pathway, UDP-GlcNAc 2-
epimerase/ManNAc kinase (Gne) and renin binding protein (Renbp), were knocked out. This was 
followed by exogenous supplementation with high-flux tri-butyrated mannosamine analogs (1,3,4-
O-Bu3ManNAc and 1,3,4-O-Bu3ManNAz) in order to modulate CHO sialylation and install non-natural 
chemical moieties. Elimination of Gne and Renbp resulted in lower sialylation relative to wild type 
cells, however analog supplementation could still improve sialylation in a concentration dependent 
manner. Despite lower basal levels of sialic acid the Gne and Renbp knockout CHO cells showed a 
higher percent incorporation of the azide modified analog. Overall, these results provide evidence 
that this strategy could be used to develop biopharmaceuticals with a more homogenous glycoprofile 
and with increased incorporation of functional groups for bioconjugation. The second portion of this 
project aimed to develop a CHO cell line producing the coagulation factor IX (FIX) with “humanized” 
sialylation and an augmented serum half-life. A CHO cell line expressing ST6GAL1, a sialyltransferase 
found in humans but naturally silent in CHO cells, and producing FIX was successfully created. FIX 
will provide an excellent test protein to demonstrate that the Yarema Lab’s metabolic analogs can be 
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Chapter 1: Introduction  
1.1 Overview  
The goal of this first chapter is to introduce the reader to key concepts and ideas that are relevant 
to understanding this thesis project. This section begins with an overview of glycosylation including 
the three main types: N-linked, O-linked, and glycolipids. This is followed by a discussion on how 
glycoengineering is being used to augment biopharmaceutical products with a special emphasis on 
metabolic glycoengineering (MGE). Each subsequent chapter also includes brief introductory 
information that is specifically pertinent to that chapter. Portions of this chapter have been published 
as Improving Immunotherapy through Glycodesign in Frontiers in Immunology (1).  
1.2 Glycosylation 
All of life is composed of four primary classes of macromolecules: proteins, nucleic acid, lipids, 
and carbohydrates. Carbohydrates are biomolecules made of carbon, hydrogen and oxygen atoms 
although other elements may be present in some variants. The simplest forms of carbohydrates are 
referred to as monosaccharides, which cannot be further hydrolyzed and take on the general 
chemical formula CnH2nOn (2, 3). Monosaccharides are commonly combined together through 
glyosidic linkages between the anomeric carbon of a sugar donor and a hydroxyl oxygen of an 
acceptor sugar resulting in the formation of carbohydrate chains called oligosaccharides and 
polysaccharides. The formation of polysaccharides and their attachment to other organic 
biomolecules, particularly proteins, is broadly referred to as glycosylation.  Glycosylation is unique 
compared to other types of macromolecules in that its synthesis is not template driven and its 
potential structural diversity is orders of magnitude larger. These inherent properties of 
glycosylation lead to enormous complexity making it both difficult to study and challenging to predict 
(2, 4). Yet, the enormous complexity is critical for many specific biological functions and provides 




the three main types of glycosylation (N-linked, O-linked, and glycolipids) including their general 
chemical composition, biosynthesis, and some critical biological roles.   
1.2.1 N-Linked Glycans 
N-Glycans are oligosaccharides covalently linked to the amide nitrogen of asparagine; they 
constitute one of the most common and almost certainly the most complex types of  post-
translational modification (PTM) (5, 6). This section provides an overview of the general process by 
which mammalian N-glycans are synthesized and covalently attached to proteins. 
1.2.1.1 Early Stages in N-Glycan Biosynthesis 
N-Glycan biosynthesis occurs in two distinct stages in the endoplasmic reticulum (ER) and the 
Golgi apparatus, respectively (6, 7). The first stage of N-glycan biosynthesis is highly conserved and 
begins in the ER with the synthesis of the lipid-linked oligosaccharide (LLO) structure. This process 
begins with the transmembrane insertion of dolichol into the ER membrane. Dolichol is an isoprenoid 
lipid made of five carbon isoprene units that functions as an oligosaccharide carrier during early LLO 
synthesis (6, 8, 9). Once dolichol has been phosphorylated (dolichol-P) a family of 
glycosyltransferases encoded by the ALG (asparagine linked glycosylation) genes act sequentially to 
synthesize the complete LLO. In mammals, Dpagt1, a GlcNAc-1-phosphotransferase, initiates this 
process by catalyzing the transfer of GlcNAc-1-P from UDP-GlcNAc to dolichol-P forming dolichol-P-
P-GlcNAc (10). The second GlcNAc residue is then added through the catalysis of a bipartite protein 
complex comprised of Alg13 and Alg14 (7, 11). Subsequently, five mannose residues are transferred 
from GDP-mannose by a series of three mannosyltransferases (Alg1, Alg2, Alg11) forming 
Man5GlcNAc2-P-P-dolichol, the final product on the cytoplasmic side of the ER membrane. This 
glycolipid is translocated into the ER lumen by a flippase (12, 13) where it is further elaborated to the 




oligosaccharyltransferase to an asparagine residue in the consensus motif Asn-X-Ser/Thr (X cannot 
be proline) of a nascent polypeptide chain during its translation across the ER membrane (14, 15).  
1.2.1.2 N-Glycan Processing and Structural Diversification  
The second phase of N-glycan biosynthesis encompasses the processing of LLOs into three 
general categories (high mannose, hybrid, and complex) which can be decorated with thousands of 
potential structural motifs (16-18) after transport of the host protein from the ER to the Golgi. This 
diversification of N-glycans – being a non-template based process – results in numerous and difficult 
to predict glycoforms. As described below, the sequential modification with mannose, GlcNAc, 
galactose, fucose, and sialic acid modulates many aspects of biology (5). 
N-Glycan processing begins in the ER with the sequential cleavage of the three glucose moieties 
of the LLO glycan structure via -glucosidase I (Mogs) and II (Ganab) (19). The removal and re-
addition of up to one glucose group is critical for calnexin and calreticulin mediated regulation of the 
glycoprotein folding process (20-22). Removal of the innermost glucose residue signals the 
glycoprotein is correctly folded, enabling ER -mannosidase I (Man1b1) to remove the outermost 
(1,2)-Man from the central arm resulting in Man8GlcNAc2, thereby signaling the glycoprotein is 
ready for further processing in the cis-Golgi. 
In the cis-Golgi after removal of the innermost glucose residue a proportion of the Man8/9GlcNAc2 
structures avoid further modification (beyond the cleavage of mannose residues to form Man5-
9GlcNAc2) resulting in high mannose type N-glycans (6) that affect glycoprotein secretion, folding, 
and stability (23). In most cases, high mannose type N-glycans are further processed in the Golgi 
resulting in hybrid- and complex-type N-glycans. The process of N-glycan branching and elongation 
begins in the medial-Golgi with the transfer of GlcNAc to the Man5GlcNAc2 structure by N-
acetylglucosaminyltransferase, Mgat1 (24). For hybrid N-glycans, the high mannose branch remains 




or capped with sialic acid, or fucose. Complex type N-glycans have two additional mannose residues 
cleaved by -mannosidases (Man2a1 or Man2a2) to produce GlcNAcMan3GlcNAc2 (25), which is 
elaborated with bi- (and sometimes tri-, and tetra-) antennary branches by the sequential addition 
of GlcNAc residues via Mgat2, Mgat4, and Mgat5. The GlcNAc transferases have decreasing affinity 
(higher Km values) for the substrate UDP-GlcNAc creating an ultrasensitive cascade that usually limits 
branching to bi-antennary structures (Fig. 1.1) (24, 26). 
The discerning reader may have noted the curious omission of Mgat3 from the previous 
paragraph; the reason is that this enzyme is an outlier that counteracts several aspects of N-glycan 
diversification and elongation. Specifically, Mgat3-catalyzed addition of GlcNAc to the -mannose of 
an N-glycan in a bisecting orientation (27, 28) inhibits the activity of Mgat4 and Mgat5 negating tri- 
and tetra-antennary branching (and subsequent elongation of the resultant antennary branches) and 
also reduces core fucosylation (Fig. 1.1) (24, 29, 30). Although only a single monosaccharide, the 
ability of bisecting GlcNAc to block subsequent branching and core fucosylation has a disproportional 
impact on overall N-glycan structure and bioactivity (e.g., in cancer metastasis (31-34), 
apolipoprotein B function (35) and the epithelial-mesenchymal transition (36, 37)). 
After GlcNAc has been added to a nascent N-glycan to form hybrid or complex structures, this 
moiety is commonly elongated with galactose by a (1,4)-galactosyltransferase, which creates the 
Gal-(1-4)-GlcNAc unit known as “LacNAc” (38, 39). Additional galactose residues may be added by 
(1,4)- or (1,3)-galactosyltransferases, either consecutively or interspersed with other 






Figure 1.1 Branch elongation and structural diversity of N-glycans (1). The Glc3Man9GlcNAc2-P-P-dolichol 
LLO structure is synthesized in the ER where it is further processed and transferred to the Golgi resulting in 
high mannose (e.g., Man5GlcNAc2), hybrid, and complex type N-glycans that undergo branching via Mgat1, 2, 4, 
and 5 GlcNAc transferase activity that respectively creates di-, tri-, or tetra-antennary structures. Following the 
initial branching step, the glycan structure may be fucosylated or undergo additional elongation and capping 
modifications (top panel). Alternatively, Mgat3 may add a bisecting GlcNAc residue which blocks Mgat4 and 5 
activity thereby preventing tri- and tetra-antennary branching and further terminal diversification (bottom 
panel). The presence of a bisecting GlcNAc also hinders core fucosylation (red triangle) and reduces the 
capacity for downstream elongation and capping. [All glycan symbol structures in this figure and throughout 









Hybrid and complex type N-glycan branches often end with GlcNAc or galactose but can also be 
decorated with fucose or terminally capped with sialic acids, meaning that typically once these sugars 
are added, the oligosaccharide chain cannot be further elongated. Fucose is a prevalent modification 
of the complex type N-glycans; in humans fucosyltransferases add this sugar in an (1,2) (FUT1,2), 
(1,3/4) (FUT3-7,9), or (1,6) (FUT8) orientation; in all mammals, Fut8 adds a fucose residue 
exclusively to the innermost Asn-linked GlcNAc group (a.k.a., “core” fucosylation). Fucose can also be 
added as a capping moiety to an outermost galactose by Fut1,2 forming Lewis and blood group 
antigens (41, 42).  
Sialic acids – a family of -keto acids comprised of a nine carbon backbone with over 50 different 
variants – ubiquitously cap glycans (5, 6, 43). N-Acetylneuraminic acid (Neu5Ac), modified with an 
N-acetyl group at the C-5  position, is the predominant sialic acid in humans and is typically found at 
the termini of N-glycan branches where it is added to the penultimate galactose via (2,3)-, (2,6)-, 
or less commonly, (2,8)-sialyltransferases (throughout the remainder of this thesis mention of sialic 
acid refers to Neu5Ac unless otherwise stated) (44, 45).  Depending on its linkage (e.g., (2,3)- vs. 
(2,6)-) Neu5Ac exhibits numerous biological functions in nervous system embryogenesis, cancer 
metastasis, immune responses, and protein bioactivity and stability (45, 46).   
1.2.2 O-Linked Glycans 
O-Glycans are monosaccharides or oligosaccharides covalently linked to a serine or threonine 
residue. Similar to N-glycans, O-glycan synthesis is not template based and is defined by a vast array 
of possible structural permutations that have many important biological and pathological functions 
including: protein stability, structure, folding, activity, metabolism, cell signaling, cell-cell 
interactions, and oncogenesis (47-50). This section focuses on synthesis and structural diversity of 




1.2.2.1 O-GalNAc Glycans 
Mucin-type O-glycans, so named because of their abundance in mucins (and their initial isolation 
and characterization from mucus), are defined by having a GalNAc at the reducing terminus (47). 
Biosynthesis of mucin-type O-glycans begins in the Golgi with the transfer of GalNAc to a serine or 
threonine residue by one of ~22 GalNAc transferases (51-53). While possible, a single unextended 
GalNAc (Tn antigen) is uncommon, instead various glycosyltransferases generate one of eight core 
structures (Fig. 1.2) (49, 50). These core structures can be further elongated and capped (generally 
with GlcNAc, galactose, sialic acid, or fucose) to create numerous motifs such as the Lewis antigens 
(e.g., Ley, Lex, sLex, Lea, sLea, Leb), thereby substantially increasing structural diversity (47, 50, 54). 
Mucin-type O-glycans are involved in many biological functions including fertilization, signal 









Figure 1.2 Structural diversity of mucin-type O-glycans (1). Mucin type O-glycan biosynthesis begins with 
the transfer of GalNAc to serine or threonine. The GalNAc monosaccharaide can be left unmodified, but is 
typically extended to create eight different core structures that can be further modified with single 
monosaccharides, Lewis structural epitopes, blood group antigen groups, or other glycan epitopes (e.g., the 
cancer-related sT or sTn antigens). 
 
1.2.2.2 O-GlcNAc Glycans 
O-GlcNAc is an uncharged acetylated hexosamine sugar that modifies serine or threonine 
residues on nuclear, mitochondrial, and cytoplasmic proteins. The O-GlcNAc modification is unique 
in that it is rarely elongated and is often times added and removed numerous times during a protein’s 
lifetime. O-GlcNAc has been implicated in many biological roles especially those relating to cellular 
signaling pathways and disease progression (55, 56).   
O-GlcNAc is synthesized via the hexosamine biosynthetic pathway (HBP) which is an offshoot of 




GlcNAcylation. In humans the pathway begins with its rate limiting step, the conversion of fructose 
6-phosphate and glutamine to glucosamine 6-phosphate and glutamate catalyzed by glutamine: 
fructose 6-phosphate transaminase (GFAT). Glucosamine 6-phosphate combines with acetyl-
coenzyme A to form GlcNAc 6-phosphate and coenzyme A which is catalyzed by glucosamine-
phosphate N-acetyltransferase (GNPNAT). Next, GlcNAc phosphomutase (PGM3) isomerizes GlcNAc 
6-phosphate to GlcNAc 1-phophate. The HBP ends with the conversion of UTP and GlcNAc 1-
phosphate to UDP-GlcNAc catalyzed by UDP-N-acetylglucosamine pyrophosphorylase (UAP1). HBP 
production of UDP-GlcNAc is considered a nutrient sensing pathway as the levels of UDP-GlcNAc can 
be directly correlated with the relative abundance or lack of various critical macromolecules. The 
transfer of O-GlcNAc on and off proteins is controlled by two enzymes O-GlcNAc transferase (OGT) 
and nucleocytoplasmic -N-acetylglucosamineidase (OGA). OGT catalyzes the transfer of GlcNAc 
from UDP-GlcNAc to a serine or threonine residue of a protein, while OGA catalyzes the reverse 
reaction. O-GlcNAc cycling is both rapid and dynamic, however regulation of OGT is convoluted and 
poorly understood (55-57).  
1.2.2.3 Other Types of O-Glycans 
O-Fucose and O-glucose are a highly specific form of glycosylation that strictly modifies the 
hydroxyl groups of serine and threonine residues within epidermal growth factor (EGF) repeats of a 
limited number of proteins (~100 and ~50 in humans, respectively). Fucose is transferred from GDP-
fucose to the serine or threonine residue of EGF repeats containing the consensus sequence 
C2X4(S/T)C3 (where C2 and C3 are the second and third conserved cysteines of the EGF-like repeat) 
by  protein O-fucosyltransferase 1. The fucose residue can then be further elongated by a series of 
GlcNAc, galactose, and sialic acid transferases (48). O-Fucose has been heavily implicated as an 
important player in the Notch signal transduction pathway which is vital for numerous biological 
functions including neuronal development, angiogenesis, and cell differentiation (48, 58).  O-Glucose 




cysteines (i.e. C1 and C2) of EGF repeats. The O-glucose modification has also  been shown to impact 
the Notch signal transduction pathway to some degree and the inability to produce this specific PTM 
is associated with various congenital diseases (48).  
O-Mannose glycans are a more common PTM that have a diverse set of potential chemical 
structures, but can be generally divided into three core classes: M1, M2, and M3. In the ER, mannose 
is added to a serine or threonine residue from a dolichol-P-mannose donor by a heterodimer made 
of protein O-mannosyltransferase 1 and 2. Core M1 O-mannose glycans are generated by the addition 
of a (1,2)-GlcNAc to the base O-mannose residue catalyzed by an N-acetylglucosaminyltransferase. 
From here, core M1 O-mannose glycans may be converted to core M2 type O-mannose glycans by the 
addition of a (1,6)-GlcNAc to the core O-mannose. M1 and M2 O-mannose glycans may be further 
elaborated by various galactose, fucose, glucuronic and sialic acid transferases leading to significant 
structural diversity. Core M3 type O-mannose glycans are generated by the addition of a GlcNAc 
residue in a (1,4) orientation. This disaccharide is specifically elongated with a GalNAc residue 
followed by the addition of two ribitol-5-phosphate groups and finally the addition of a repeating 
disaccharide called matriglycan. Broadly, O-mannose is vital for normal development and growth and 
has been identified as a key player in multiple diseases including congenital muscular dystrophy, 
viral entry, and cancer metastasis (48, 59).  
1.2.3 Glycolipids 
Glycolipids are the third class of glycosylation, broadly defined as amphiphilic macromolecules 
composed of a hydrophilic polar carbohydrate group connected to a hydrophobic apolar lipid group 
through a glyosidic bond. The sugar portion of glycolipids can be highly variable with a range of sizes 
and complexities. Due to the lipid moiety, glycolipids are most often anchored in a molecular 
membrane, but can still perform a variety of biological functions including recognition, adhesion, and 




1.2.3.1 Glycosphingolipids  
Mammalian glycosphingolipids (GSLs) are one subclass of glycolipids and are comprised of a 
sphingolipid, fatty acid, and carbohydrate (Fig. 1.3A). GSLs are the predominant form of glycolipid 
found in vertebrates and are vital for numerous biological functions including cellular adhesion, cell-
cell interactions, signal transduction, oncogenesis, ontogenesis, and immunogenicity (61-63).  The 
biosynthesis of GSLs is a stepwise process beginning with the synthesis of ceramide in the cytosol 
and subsequent transfer to the luminal ER. From here, typically glucose or galactose is the first glycan 
added to ceramide.  Glucose is added to ceramide (GlcCer) on the cytoplasmic face of the ER and early 
Golgi where it can be further elaborated by a series of glycosyltransferases forming one of seven base 
tetrasaccharide neutral sugar core structures (Fig. 1.3B). Conversely, galactose can be added to 
ceramide (GalCer) on the luminal face of the ER and transported to the Golgi where a sulfate is added 
to form sulfatide which may be sialylated, but is otherwise rarely elongated with other 
monosaccharide units (Fig. 1.3C) (61).  
1.2.3.2 Glycosylphosphatidylinositol Anchors 
The second major form of glycolipids is glycosylphosphatidylinositol (GPI), a PTM attached to the 
C-terminus of proteins to anchor cell surface proteins in a lipid membrane. GPI-anchored proteins 
usually face the extracellular surface and at least 150 GPI-anchored proteins are found in humans. 
The only known biological role of GPI itself is to provide a stable membrane anchor for proteins, 
however GPI-anchored proteins are critical for a variety of biological purposes including: signal 
transduction, immune response, adhesion, protease inhibition, and disease progression. Nearly all 
GPI anchors share the ubiquitous base structure ethanolamine-PO4-6Man(1,2)Man(1,6)- 
Man(1,4)GlcN(1,6)myo-inositol-1-PO4-lipid which can be modified at various locations to 
generate considerable chemical diversity. A GPI precursor is synthesized on a phosphatidylinositol 




protein in the lumen of the ER. From here, the GPI-protein is chemically modified in the ER and Golgi 
leading to vast heterogeneity in the final GPI-protein structure (64-66).  
 
 
Figure 1.3 Structures and classes of glycosphingolipids. (A) Glycosphingolipids are comprised of a 
sphingoid base and fatty acid (forming ceramide) conjugated to a carbohydrate via a glyosidic bond. (B) Most 
commonly, ceramide is linked to a glucose residue which can be further elaborated into one of seven 
tetrasaccharide neutral core structures. (C) Ceramide may also be conjugated to galactose which is 







1.3 Glycoengineering for Biopharmaceutical Applications 
Biopharmaceuticals, defined as any biologically derived therapeutic product, continue to be one 
of the predominant therapies for a wide range of disease. Biopharmaceuticals encompass a variety 
of different products including monoclonal antibodies (mAbs), clotting factors, growth factors, 
hormones, stem cells, vaccines, and interleukins (Fig. 1.4). From 2010 – 2014 the Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) approved 54 new biopharmaceutical 
products (67). Furthermore, in 2016 the biopharmaceutical industry totaled approximately 228 
billion USD in global sales (68) and current market projects expect a compound annual growth rate 
of 8.59% between 2018 – 2023 (69). In order to maintain this robust growth and to develop the next 
generation of biopharmaceuticals the industry is starting to focus considerable effort on 
glycosylation, which plays a pivotal role in both the efficacy and safety of biopharmaceuticals (70). 
This section begins by discussing considerations for selecting a cell system with an emphasis on how 
glycosylation impacts this decision. This is followed by a section highlighting various genetic 
glycoengineering strategies that have been used to manipulate the glycoprofile of 
biopharmaceuticals. Lastly, this section discusses MGE technology with a focus on how it can be used 




Figure 1.4 Overview of common biopharmaceuticals (1). (A) Biopharmaceuticals is a broad term that refers 
to any therapy created using material derived from a living system, several examples are shown. (B) Protein-
based biologics dominate today’s commercial products including mAbs and interferon. (C) Until a few decades 
ago, vaccines dominated the biopharmaceutical landscape, a 200-year old endeavor, with cancer vaccines 
representing one example of this trend today. (D) The extraordinarily diverse nature of biopharmaceuticals is 
illustrated by emerging cell-based and gene therapies. 
 
1.3.1 Cell Host Selection  
Early generations of biopharmaceuticals, such as vaccines, largely were produced in 
embryonated eggs or collected from animal products and human blood donations (71, 72). Most of 
today’s biopharmaceuticals, however, exploit recombinant DNA technology to produce proteins in 




themselves). Cell-based biomanufacturing efforts have explored a wide range of expression systems 
including non-mammalian (bacteria, yeast, plant, and insect) and mammalian (human, hamster, and 
mouse) cells (73) to optimize product yield and install appropriate PTMs. From 2004 to 2013 
biopharmaceuticals approved by the FDA and EMA were obtained from mammalian cells (56%), 
Escherichia coli (24%), Saccharomyces cerevisiae (13%), insect cells (4%) and transgenic animals and 
plants (3%) (74). The majority of products, obtained from mammalian cells, includes virtually all 
recent therapeutic proteins where PTMs, especially glycosylation, can be optimized for safety, 
biological activity, function, stability, physicochemical properties, and pharmacokinetics (46, 75, 76). 
For this reason – after providing a brief synopsis of non-mammalian options – this section will focus 
on the selection of mammalian expression systems used in biomanufacturing beginning with the use 
of human and murine cell lines used in the early production of modern biopharmaceuticals. As 
discussed below, each of these cell lines has substantial pitfalls, leading to today’s consolidation of 
production in CHO cells. 
1.3.1.1 Non-Mammalian Cell lines 
Insulin, the earliest recombinant human protein, was produced in E. coli, which benefits from low 
cost and high productivity (74, 77). Although a few biologics are still produced in E. coli, the lack of 
N-glycans (that ensure quality control during folding) (78) makes prokaryotic production untenable 
for most glycoproteins including mAbs. Yeast (S. cerevisiae and Pichia pastoris) provide another high 
productivity, low cost production platform (79, 80) and – being eukaryotic cells – do have N-glycans; 
yeast glycans, however, tend to be highly mannosylated which reduces serum longevity thus 
compromising pharmacokinetics and also impacting downstream effector functions (81). Even 
though efforts have been made to “humanize” yeast glycosylation, these cells have not become a 
widely-accepted biomanufacturing platform (81). Finally, insect (e.g., Trichoplusia and Drosophila) 




humanize glycosylation (82, 83), these cells also have substantial pitfalls for biomanufacturing 
including minimal sialylation ability (82, 84).  
1.3.1.2 Human Cell Lines 
The inability of the initial bacterial, yeast, and insect production platforms to produce properly 
glycosylated human proteins led to production efforts in human cells. The first immortalized human 
cell line, HeLa, was derived from cervical cancer in 1951 (85) and paved the way for the development 
of other immortalized human cell lines, notably human embryonic kidney 293 (HEK293) and 
fibrosarcoma HT-1080 cells used to produce viral vaccines (86-88). However, it wasn’t until ~2001 
that the first therapeutic glycoprotein produced in human cells (HEK293), Drotecogin alfa, was 
approved by the FDA and EMA; since then several glycoprotein biopharmaceuticals have been 
produced in human cells primarily in the HEK293 and HT-1080 lines (73).  
Human cells offer important advantages over other production platforms including the ability to 
closely mimic PTMs, particularly glycosylation, naturally found in people. For example, human cell 
lines express MGAT3, (1,3/4)-fucosyl transferase, and (2,6)-sialyltransferse (ST6GAL1) which are 
silent or missing in CHO cells. Furthermore, human cell lines do not produce immunogenic structures, 
such as -Gal and N-glycolylneuraminic acid (Neu5Gc), thus minimizing safety and compatibility 
concerns. These factors reduce the need to genetically engineer cells and limit the cost of 
downstream processing (86, 87, 89).  Although human cells have these attractive features as a 
production platform, they also have substantial limitations and drawbacks. For example, human lines 
suffer from low growth rates, production capacities, and protein yields making them impractical for 
the production of many therapeutic proteins including most mAbs. Furthermore, the absence of a 
species barrier makes human cell lines a significant safety risk due to the potential for contamination 




advances in technology and adherence to stringent good manufacturing practices (86, 87, 89); in 
practice, most biopharmaceuticals are now produced in rodent cells, as described next. 
1.3.1.3 Murine Cell Lines 
Murine myeloma cells, predominantly NS0 and Sp2/0, are another cell platform that is 
periodically used for the production of recombinant glycoproteins. Both the NS0 and Sp2/0 cell lines 
were developed from tumors and subsequently genetically engineered to stop producing their native 
immunoglobins yet retain the cellular machinery to secrete recombinant proteins at high levels (90, 
91). Accordingly, these lines have been used to produce the commercial mAbs Cetuximab, 
Palivizumab, Dinutuximab, Necitumumab, and Elotuzumab (73, 87, 92).  A downside of murine cells 
is their ability to incorporate -Gal and Neu5Gc into glycans, thereby presenting a considerable risk 
of immunogenicity (93-95). Thus, murine cells used for therapeutic protein production must be 
thoroughly screened for clones lacking these immunogenic epitopes while producing desirable 
glycan profiles.  
1.3.1.4 Chinese Hamster Ovary Cells  
In 1986 tissue plasminogen became the first FDA-approved recombinant biopharmaceutical to 
be produced in CHO cells (87, 89, 96); since then these cells have become the predominant 
manufacturing platform for biologics producing an estimated 70% of recombinant 
biopharmaceutical proteins (76, 97, 98). Furthermore, over 90% of commercial antibodies are now 
produced in CHO cells (67, 73, 87). The success of CHO cells in commercial biomanufacturing stems 
from several key advantages. First, CHO cells can be grown in large bioreactors as a cell suspension 
in serum-free, chemically-defined media while maintaining high production rates. From a safety 
perspective, many viral entry genes are not expressed in CHO cells and there is a species barrier that 
minimizes risk of transferring infectious agents to humans (99, 100). Furthermore, over the past 




approval to bring biopharmaceutical products to the market (89, 96). Perhaps most importantly, CHO 
cells produce recombinant glycoproteins with compatible glycoforms that are bioactive in humans 
(73, 87, 96, 101).  
Despite the advantages of CHO cell production platforms, shortcomings exist. CHO cells (as with 
most mammalian cell lines) retain the ability to produce glycans not found in humans including -
Gal and Neu5Gc (94, 102). Humans inherently express antibodies against these immunogenic 
epitopes that can lead to severe, potentially fatal immunogenic responses and/or negate the effects 
of biotherapeutics (93-95). However, the levels of -Gal and Neu5Gc are relatively low (<2% Neu5Gc 
and <0.2% -Gal) in CHO cells, meaning this issue can be circumvented by selecting clones lacking 
these non-human epitopes (73, 94). CHO cells also lack certain types of glycosylation found in 
humans, such as (2,6)-sialylation, (1,3/4)-fucosylation, and bisecting GlcNAc (103-106). 
Overcoming these differences by “humanizing” CHO cell glycosylation is, at least in theory, possible 
through genetic engineering and MGE approaches.   
1.3.2 Genetic Glycoengineering  
Various approaches to modulate glycans in living cells – i.e., glycoengineering methods – have 
been developed over the past three decades concurrent with the unraveling of the importance of 
glycosylation in immunity. Today, these parallel developments have set the stage to employ the 
various glycoengineering strategies now available to generate recombinant proteins (or even entire 
cells) with desirable glycan profiles (104, 105, 107) during biopharmaceutical design and 
manufacturing. Glycoengineering falls into two main approaches: genetic and metabolic; this section 
discusses specific examples of both approaches while describing general strengths and drawbacks to 
each approach. Although glycoengineering strategies are being developed for many production 
platforms (bacteria (106), yeast (108), plants (109), insects (110)), this section will focus on 




Many genetic approaches have been used to target glycosylation pathways and enzymes via gene 
knockdown, knockout, overexpression, knock-in, and selective nucleotide mutation. These genetic 
engineering strategies have been used to reduce or silence undesirable glycosyltransferase activities, 
enhance glycosyltransferase activities, activate endogenously silent genes, introduce new glycosites, 
mimic hypomorphic disease mutations, and insert foreign genes (109). In recent years, genetic 
glycoengineering has been galvanized by the discovery and development of zinc-finger nucleases, 
transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short 
palindromic repeats (CRISPR)-CRISPR-associated protein (Cas) technology (109, 111, 112). A 
strength of genetic approaches is their versatility and ability to make permanent cellular 
modifications; however, genetic approaches have limitations such as off-target effects, inefficient in 
vivo delivery systems, confounding epigenetic regulation of glycosylation pathways, and 
unpredictable alterations to cellular physiology (109, 113).  
Sialic acid is one of the most frequently targeted monosaccharides for glycoengineering due to its 
manifold impact on the pharmacokinetics of recombinant glycoproteins and its specific impact on 
bioactivity in antibody-dependent cellular cytotoxicity (ADCC), intravenous immunoglobin (IVIG) 
therapy, and antibody-drug conjugates (ADCs). Of particular interest, sialic acid masks the 
penultimate galactose and GlcNAc residues from the hepatocyte asialoglycoprotein receptor 
inhibiting protein endocytosis and clearance from circulation (114, 115). This effect is bolstered by 
the net negative charge of sialic acid which reduces proteolytic degradation and subsequent 
clearance of the protein by the kidneys due to the cationic and anionic elements within the renal 
glomerular basement membrane and epithelium (70, 116, 117).  
Genetic manipulation of sialyltransferases constitutes a common approach to glycoengineer 
sialic acid; in particular expression of -galactoside (2,6)-sialyltransferases (usually ST6GAL1) in 
CHO cells enables the production of glycoproteins with both (2,3)-sialic acids (from the cells’ 




similar to glycoproteins produced in humans (112, 118-120). In addition, overexpression of ST6GAL1 
(or other sialyltransferases) increases the overall sialylation of therapeutic glycoproteins including 
erythropoietin (EPO) (120-122), tissue plasminogen activator (119, 123), interferon  (IFN-) (124, 
125), and immunoglobin G (IgG) (123, 126, 127). Other studies have targeted the preceding step, the 
addition of galactose, to enhance terminal sialylation levels. Multiple studies have demonstrated that 
concomitant over-expression of (1,4)-galactosyltransferase and (2,3)-sialyltransferase in CHO 
cells yields increased sialylation and galactosylation in EPO, IgG, and tissue plasminogen activator 
(121, 123). Another strategy is to overexpress Mgat4 and 5 to increase tri- and tetra-antennary 
branched N-glycans, thereby creating more sites for terminal sialylation; this strategy has been 
employed in EPO (122), albumin EPO (128), and IFN- (129, 130).  
Another strategy for improving sialylation targets enzymes and transporters in the SABP to 
increase CMP-Neu5Ac levels. One approach recapitulated point mutations in the bifunctional enzyme 
GNE associated with sialuria (131, 132), a congenital disease that leads to excessive synthesis of sialic 
acid due to the absence of feedback regulation (133), which led to increases in intracellular CMP-
sialic acid levels and EPO sialylation (134, 135). Although increasing intracellular CMP-Neu5Ac levels 
can increase glycoprotein sialylation there may be a saturation point due to the inefficiency of the 
CMP-sialic acid transporter responsible for transporting CMP-Neu5Ac to the Golgi. To overcome this 
barrier one study overexpressed CMP-sialic acid transporter in CHO cells, but only saw modest 
increases (4% - 16%) in IFN- sialylation (136). Inhibiting or eliminating sialidases (or 
neuraminidases) is a complementary strategy for enhancing glycoprotein sialylation levels and 
retention times; these enzymes are glycosidases that catalyze the hydrolytic removal of sialic acid 
from glycoproteins, glycolipids, and polysaccharides (137). One study utilized short interfering RNA 
and short-hairpin RNA to lower expression of the Neu1 and Neu3 sialidase in CHO cells, which 




In a different approach, genetic glycoengineering can be utilized to introduce new glycosites into 
glycoproteins through creation of the Asn-X-Ser/Thr consensus sequence for N-glycosylation. This 
approach is illustrated by darbepoetin alfa, a genetically modified form of EPO that has five (instead 
of three) N-glycan sites (139); this enhanced level of glycosylation improved serum longevity ~3-fold 
(139), but was accompanied by adverse effects such as increased risk of stroke (140). (As a caveat, 
there is no evidence that increased risk is a general feature of over-glycosylated therapeutic proteins 
beyond darbepoeitin alfa or a direct consequence of the newly-installed glycans). Another interesting 
example of building in N-glycosites is provided by Ibalizumab, where the strategic addition of an N-
glycan to this mAb improves its HIV-neutralizing activity (141).   
1.3.3 Metabolic Glycoengineering   
The second major strategy to control glycosylation is MGE, where living cells or entire organisms 
are supplemented with monosaccharide precursors that either increase natural flux through a 
biosynthetic pathway or increasingly, substitute natural metabolites with their non-natural 
counterparts. The exogenously-supplied synthetic monosaccharides are processed by the 
biosynthetic pathway, ultimately yielding glycans with enhanced glycoforms (e.g., improved 
sialylation) or non-natural chemical groups (142-144). One advantage of MGE is its simplicity, where 
an analog can be directly added to cell culture medium to exploit the intrinsic cellular machinery 
without any need to genetically manipulate the host cell, thus averting off-target complications. 
However, MGE can be non-trivial due to the need for custom synthesis of the required 
monosaccharides and expensive to implement on an industrial scale because their concentration in 
culture media must be maintained to obtain a desired glycan profile (142, 143).  
One of the most common uses of MGE has been to increase the sialylation of recombinant proteins 
to improve their serum half-life. Numerous MGE strategies have aimed to take advantage of sialic 




of the most common and effective strategies has been to supplement cells with ManNAc or chemically 
modified ManNAc analogs (145). The permissiveness of the SABP was discovered accidently by the 
Sartorelli group when trying to use a fluorinated ManNAc analog to block sialylation in cancer cells 
(146, 147). Instead of blocking sialic acid production the fluorinated ManNAc analog was 
incorporated into the pathway and subsequently displayed in cell surface glycosylation. The Reutter 
group built on this initial discovery by developing hexosamine analogs capable of installing non-
natural monosaccharides on cell surface glycans (144, 148). Since these breakthroughs ManNAc has 
become the prevailing base unit for MGE analogs because of (i) cost, (ii) synthetic amenability, (iii) 
and high tolerability for incorporation into the SABP (1, 142, 143). In some cases, even unmodified 
ManNAc has been shown to increase free intracellular and protein sialic acid levels. In one study 
supplementing CHO cells with 20 mM ManNAc increased the intracellular CMP-sialic acid pool by 30-
fold and recombinantly produced IFN- sialylation increased by at least 15% (30). This result was 
later corroborated by a study which found that addition of 20 mM ManNAc to CHO cells led to a 30-
fold increase in CMP-sialic acid levels and a 32% increase in recombinant IFN- sialylation (149). In 
contrast, a different study found that tissue inhibitor of metalloproteinase 1 recombinantly produced 
in CHO and NS0 cells supplemented with 20 mM ManNAc did not lead to any change in sialylation 
levels despite increases in intracellular CMP-sialic acid (150). Additionally, experiments by Hills et al. 
found that adding 20 mM ManNAc to NS0 cells did not increase recombinantly produced IgG 1 
sialylation despite a 44-fold increase in intracellular CMP-sialic acid levels (151). These seemingly 
conflicting results may be attributed to the accessibility of the protein glycosites to sialyltransferases 
exemplified by the sterically hindered location of IgG fragment crystallizable (Fc) N-glycans (151, 
152). One major pitfall of using unmodified ManNAc is the requisite high concentrations (≥20 mM) 
rendering this strategy economically infeasible for production of recombinant proteins at an 




The shortcomings of unmodified ManNAc has led to the development of chemically modified 
versions of ManNAc with augmented uptake efficiency. To this end, our group peracetylated ManNAc 
creating Ac4ManNAc which is metabolized and incorporated into the SABP 900-fold more efficiently 
than natural ManNAc. This allows Ac4ManNAc to be used at more reasonable concentrations between 
100 – 500 µM, yet at these concentrations Ac4ManNAc is cytotoxic leading to reduced protein yields 
making this analog impractical for recombinant protein production (Fig. 1.5) (154, 155). To 
circumvent this issue our group butyrated ManNAc creating a new array of analogs including 1,3,4-
O-Bu3ManNAc which is 2100-fold more efficient than its ManNAc precursor and critically has no 
cytotoxic effects at concentrations less than or equal to 500 µM (Fig. 1.5) (156-158). Multiple studies 
have demonstrated that treating CHO cells with 300 µM of 1,3,4-O-Bu3ManNAc increased 
erythropoietin (EPO) sialylation by at least 40% while supplementation with natural ManNAc at 20 
mM resulted in only a 20% increase in EPO sialylation (159, 160). Another added benefit of this 
compound is it leads to higher protein expression in CHO cells, specifically for IgG and EPO (161). In 
theory supplementation of cell culture with 1,3,4-O-Bu3ManNAc could be extended to any 
recombinant protein to ameliorate pharmacokinetic properties and increase protein yield.  
In an alternative approach chemically modified ManNAc was used to create the analogs N-
propanoylmannosamine (ManNPr) and N-pentanoylmannosamine (ManNPe) capable of causing 
cells to produce non-natural N-propanoyl or N-pentanoyl sialic acid (144, 162, 163). When CHO cells 
producing EPO were supplemented with ManNPr or ManNPe the corresponding non-natural 
versions of sialic acid were installed in significant proportions on EPO. Critically, the glycoengineered 
EPO with N-propanoyl or N-pentanoyl sialic acid was more resistant to sialidases prolonging the 





Figure 1.5 Glycoengineering mAbs for enhanced sialylation and glycan-targeted ADC production (1). (A) 
Cells can be supplemented with ManNAc or analogs (e.g., Ac4ManNAc or 1,3,4-O-Bu3ManNAc), which intercept 
and increase flux through the SABP with the indicated relative efficiencies (“R.E.” values) increasing sialylation 
of recombinant glycoproteins, such as mAbs. (B) Alternatively, cells can be supplemented with analogs 
containing non-natural chemical moieties (e.g., Ac4ManNAz or 1,3,4-O-Bu3ManNAz to install azide groups or 
Ac46-Thio-Fuc to install thiols). These functional groups, which do not naturally occur in glycans, constitute 









In a second MGE-based approach, ManNAc analogs can be used to install non-natural chemical 
moieties into glycans, in essence creating a chemical handle for bioorthogonal conjugation of small 
molecules including toxins, drugs, genes, imaging agents and polymers (143). This strategy has been 
used to incorporate numerous non-natural functional groups such as ketones (164-166), azides (157, 
167), alkynes (168), diazirines (169), aryl azides (170), and thiols (171) into glycans for subsequent 
conjugation via click chemistry. A sialic acid-based MGE approach can be used to introduce 
conjugation sites restricted to the Fc region of mAbs for developing ADCs (155, 172, 173); similarly, 
the fucose-replacing analog 6-thiofucose can introduce thiol moieties into 70% of IgG heavy chains 
with 90% conjugation efficiency to small molecule drugs via maleimide chemistry (174). As superior 
metabolic analogs (e.g. 1,3,4-O-Bu3ManNAz (157)) and conjugation chemistries (e.g., strain-
promoted alkyne-azide cycloaddition (156, 157)) are developed MGE will continue to grow as an 
effective method for developing new biopharmaceuticals.  
On a final note, the field of MGE has often been regarded as a genetically silent method to label 
glycans based on the assumption that the glycosylation machinery of a cell is not substantially 
perturbed while processing the exogenously-supplied sugars required for this methodology. While 
this premise is basically accurate, our group (and others) have described how metabolic flux 
engendered by MGE monosaccharide analogs (and even natural sugars) can on occasion affect the 
expression of glycogenes with this effect most well studied for the SABP (175-177). The ability of MGE 
analogs to affect gene expression and cell physiology extends beyond glycogenes per se and can have 
a profound impact on cellular processes such as cell differentiation (178-180). These effects are 
mentioned both to caution researchers to the complex interplay between metabolism, genetics, and 
cell fate that can occur during MGE interventions, but also to highlight the opportunities to use this 





Chapter 2: Engineering CHO Cells for Improved Control Over 
Sialylation  
2.1 Overview 
The second chapter gives an in-depth description of the primary project for this thesis. The goal 
of this project was to use a combination of genetic engineering and MGE techniques to gain enhanced 
control over the quantity and type of sialylation produced by CHO cells. This chapter starts with a 
brief introduction to concepts important for this project that were not thoroughly discussed in 
Chapter 1. This is followed by (in order) a description of the specific aims of this project, methods, 
results, and a discussion of the current state of the project.  
2.2 Background  
This section briefly covers background information relevant to this chapter that was not 
extensively covered in the introduction. This section begins by explaining the discovery and 
mechanism of CRISPR-Cas technology. This is followed by an overview of sialic acid synthesis with 
an emphasis on the SABP.  
2.2.1 Clustered Regularly Interspaced Short Palindromic Repeats  
CRISPR-Cas technology has revolutionized genome engineering by enabling fast and precise 
modifications to be made to the genomes of a variety of organisms. The CRISPR-Cas system was 
originally discovered as part of an adaptive immune mechanism in bacteria and archaea to protect 
against phage infection and foreign plasmid transfer, but has since been repurposed as a technology 
for editing genomes (181, 182). Generally, the CRISPR-Cas system utilizes a non-specific 
endonuclease (in most cases Cas9) to cut the genome at a location specified by a guide RNA (gRNA). 
The gRNA is comprised of two components (i) a crRNA which is a ~20 nucleotide RNA strand that 




connecting the crRNA to the Cas endonuclease. The target genome site must contain an upstream (5’) 
protospacer adjacent motif (PAM) sequence to initiate Cas recognition of the target site; the most 
common PAM motif is 5’-NGG-3’ where N is any base pair. Once the Cas endonuclease recognizes the 
target genome site it creates a double stranded break in the DNA three to four nucleotides upstream 
of the PAM motif. The resulting double stranded break is then repaired by either non-homologous 
end joining (NHEJ) or homology directed repair (HDR). NHEJ is more common as it is the more 
efficient of the two pathways, however NHEJ tends to be error prone leading to random indel 
generation. Conversely, HDR has lower efficiency, but has higher fidelity enabling it to be used for 
precise genome edits (183-185). A generalized workflow for implementing CRISPR-Cas technology is 
outlined in Figure 2.1. In this way any given region of the genome may be edited with both speed 





Figure 2.1 Overview of workflow for using CRIPSR-Cas technology to 







2.2.2 Sialic Acid Biosynthetic Pathway 
Sialic acids are nine-carbon -keto acids with over 50 different variants found throughout nature. 
Neu5Ac is modified with an N-acetyl group at the C-5 position of the carbon backbone and critically 
is the most prevalent form of sialic acid in humans. Sialic acids are primarily found as the penultimate 
glycan on various glycoconjugates and have numerous critical biological functions (45). Crucial to 
this project sialic acid is known to protect proteins from metabolic degradation thereby extending 
their serum half-life (1.3.2 Genetic Glycoengineering). Sialic acids have different anabolic 
pathways in bacteria and mammals, however this section will focus on the mammalian pathway for 
the synthesis of Neu5Ac as it is most relevant to this work.  
In mammals the de novo synthesis of sialic acid occurs in the cytosol beginning with the 
epimerization of UDP-GlcNAc to ManNAc which is subsequently phosphorylated to ManNAc 6-
phosphate catalyzed by the bifunctional enzyme Gne. Gne is the rate limiting enzyme of the SABP and 
its epimerase activity is feedback inhibited by the final product of the pathway, CMP-sialic acid. 
Critically, the only other sources of ManNAc for the SABP is (i) from the epimerization of GlcNAc to 
ManNAc catalyzed by Renbp (also known as GlcNAc 2-epimerase [G2E]), (ii) the conversion of sialic 
acid to ManNAc and pyruvate catalyzed by sialic acid lyase, (iii) and nutritional sources (which 
contain only trace amounts of ManNAc) (133). In the next step Neu5Ac 9-phosphate is formed via a 
condensation reaction between ManNAc 6-phosphate and phosphoenolpyruvate catalyzed by 
Neu5Ac 9-phophate synthase (Nans). This reaction is followed by the Neu5Ac 9-phosphate 
phosphatase (Nanp) catalyzed dephosphorylation of Neu5Ac 9-phophate yielding Neu5Ac. Neu5Ac 
is then transferred to the nucleus where it is converted to CMP-Neu5Ac by the CMP-Neu5Ac 
synthetase. From here CMP-Neu5Ac is transported to the Golgi apparatus via the CMP-sialic acid 
transporter where it can finally be transferred to glycan chains via one of approximately 20 different 




2.3 Specific Aims  
MGE is a technique that uses synthetic monosaccharides similar in structure to natural 
precursors in a biosynthetic pathway to manipulate cellular glycosylation processes (1.3.3 
Metabolic Glycoengineering). Our lab has previously developed (156, 157) and characterized (158) 
novel butyrated ManNAc analogs (1,3,4-O-Bu3ManNAc and 1,3,4-O-Bu3ManNAz) capable of 
increasing metabolic flux through the SABP thereby increasing glycoprotein sialylation and installing 
non-natural chemical groups on protein sialylation (159, 160). The butyl groups enable efficient 
transport across the cellular membrane and are subsequently cleaved by nonspecific esterases to 
yield a ManNAc molecule which intercepts the SABP. In addition to increasing sialic acid levels the 
analog, 1,3,4-O-Bu3ManNAz, can be used to incorporate sialic acid with an azide moiety onto 
glycoproteins. Incorporation of non-natural chemical groups enables conjugation of various chemical 
compounds to recombinant glycoproteins. However, these analogs do not give complete control over 
quantity and type of sialic acid produced due to endogenous ManNAc flux through the SABP. ManNAc, 
which is the feedstock for the SABP, is produced endogenously in mammals by three enzymes Gne 
(133, 186), Renbp (187), and sialic acid lyase (45).  
In mammals, Gne is regarded as the primary enzyme that supplies ManNAc for incorporation into 
the SABP (133, 188). Gne is a bifunctional enzyme that catalyzes the isomerization of UDP-GlcNAc to 
ManNAc and subsequent phosphorylation to ManNAc 6-phosphate. Critically, CMP sialic acid, a 
downstream SABP intermediate, feedback inhibits the epimerase activity of Gne, thus facilitating 
MGE. Two sets of experiments illustrate the important role of Gne activity in tuning the metabolic 
incorporation of ManNAc analogs into the SABP.  First, in cells with a mutant form of Gne that lacked 
feedback inhibition, the resulting very high levels of ManNAc endogenously produced in these cells 
almost completely obliterated the incorporation of non-natural ManNAc analogs into the SABP (132, 




natural ManNAc analog uptake from endogenously-produced ManNAc into the SABP and facilitated 
cell surface presentation of the resulting non-natural sialic acids (189).   
These experiments suggested that MGE will achieve optimal efficiency in cells lacking the ability 
to produce ManNAc endogenously.  Consequently, one goal of the project was to knockout Gne, which 
is the primary endogenous source of ManNAc in mammalian cells including CHO-K1 cells commonly 
used in biomanufacturing.  There are, however, secondary routes by which ManNAc can enter the 
SABP. One mechanism is by conversion from GlcNAc through an epimerization reaction catalyzed by 
Renbp, where GlcNAc is the thermodynamically favored product under normal conditions 
(equilibrium ratio of 3.9:1) (190). Renbp can produce ManNAc if the GlcNAc to ManNAc ratio is high.  
Such an excess of GlcNAc, leading to conversion of ManNAc, is expected in Gne knockout cells (133, 
191).  Accordingly, a second goal of this project was to knockout Renbp in CHO-K1 cells in order to 
eliminate another route by which ManNAc is endogenously incorporated into the SABP (Fig. 2.2). A 
final route for ManNAc production in mammalian cells is through sialic acid lyase, which coverts sialic 
acid back to ManNAc and pyruvate.  This enzyme is primarily involved in sialoside recycling and has 
been shown to be able to salvage sialic acids present on glycoproteins in fetal bovine serum (FBS) 
used in cell culture (192).  In this project we focus on CHO cells that can be grown in reduced serum 
media, which minimizes this salvage mechanism and lessens the impact of metabolic flux competition 
on ManNAc analogs used in MGE (However, the additional knockout of sialic acid lyase is discussed 
in the context of Future Work (2.7.4 Knockout Sialic Acid Lyase).  In theory, for the first time, these 
strategies will allow for enhanced control of sialic acid levels and composition via supplementation 
with our butyrated ManNAx analogues. This project was pursued with a focus on the following 
specific aims: 
Aim 1: Eliminate competing endogenous routes for ManNAc to enter the SABP. CRISPR-Cas 
technology was used to knockout Gne and Renbp in CHO-K1 cells thereby preventing the primary 




Aim 2: Determine how knocking out the Gne and Renbp genes impacts cellular uptake and 
incorporation of 1,3,4-O-Bu3ManNAc. The genetically engineered cell lines were supplemented 
with varying concentrations of 1,3,4-O-Bu3ManNAc and levels of free intracellular sialic acid were 
analyzed through multiple assays.  
Aim 3: Determine how knocking out the Gne and Renbp genes impacts cellular uptake and 
incorporation of 1,3,4-O-Bu3ManNAz. The genetically engineered cell lines were 
supplemented with varying concentrations of 1,3,4-O-Bu3ManNAz and azide incorporation levels 







Figure 2.2 Overview of the strategy to gain enhanced control over glycoprotein sialylation levels and 
composition. To achieve this aim, a combination of genetic engineering and MGE was employed. CRISPR-Cas 
technology was used to knockout Gne and Renbp in CHO-K1 cells to cut off the primary endogenous routes by 
which ManNAc can flux into the SABP. After cell engineering, ManNAc analogs (1,3,4-O-Bu3ManNAc and 1,3,4-
O-Bu3ManNAz) were added to the cell culture media to precisely modulate sialylation levels and improve the 
percent incorporation levels of non-natural forms of sialic acid.  
 
2.4 Materials & Methods 
2.4.1 Cell Culture  
The CHO-K1 cell line (ATCC, CCL-61) was used for all cell engineering and experiments 
performed in this chapter. The CHO-K1 cell line is a subclone of the parental CHO cell line derived by 




stated otherwise CHO-K1 cells were cultured in an adherent monolayer in F-12K nutrient mixture 
(Kaighn’s modification) (Corning, 10-025-CV) supplemented with 10% (v/v) heat inactivated, sterile 
filtered FBS, 1% (v/v) antibiotic-antimycotic solution (100x) (Sigma Aldrich, A5955-100ML), and 5% 
CO2 in a humidified environment at 37 °C. CHO-K1 cells were kept at or below 1 x 105 cells cm-2 to 
prevent them from reaching a confluent and quiescent growth stage. The cells were passaged every 
three to four days by aspirating the spent media, washing once with phosphate buffered saline (PBS) 
(pH = 7.4), detached using 0.25% trypsin-EDTA (Gibco, 25200-056), and incubated in a 5% CO2, 
humidified 37 °C environment for 5 – 10 minutes. After incubation, cell detachment was verified 
using a microscope and fresh complete F-12K media was used to transfer cells to a conical tube. Cells 
were pelleted via centrifugation for 5 minutes at 1057 x g, resuspended in 5 mL of complete F-12K 
media and seeded at a density of 1 x 104 cells cm-2. Cell density was determined using a Beck Z2TM 
Coulter Particle Count and Size Analyzer (Beckman-Coulter) with a 100 µm aperture, dilution factor 
of 1:101, and boundaries set between 7 and 25 µm. Two measurements were made per sample and 
averaged to determine cell density.  
2.4.2 Mammalian Cell Cryopreservation  
CHO-K1 cells were detached, pelleted, resuspended, and counted as described above (2.4.1 Cell 
Culture). Cells were preserved by combining 10% (v/v) dimethyl sulfoxide (DMSO) with 1 x 106 cells 
suspended in fresh, complete F-12K media in a screw top cryopreservation tube. The cells were 
placed in a “Mr. Frosty” freezing container with 2-propanol and frozen in a -80 °C freezer at a 
controlled rate of 1 °C per minute. After 24 hours the cells were transferred from the “Mr. Frosty” 
freezing container to a liquid nitrogen cryopreservation vessel (final temperature -196 °C) for long 




2.4.3 Thawing Cryopreserved Cells 
Cryopreserved cells were removed from liquid nitrogen storage and thawed quickly (< 1 minute) 
in a 37 °C water bath until only a small bit of ice remained.  Prewarmed compete F-12K media was 
added to the cryopreservation tube and the cell solution was transferred to a conical tube. Cells were 
pelleted by centrifuging at 1057 x g for 5 minutes and the DMSO F-12K media supernatant was 
aspirated. The cells were resuspended in fresh F-12K media, transferred to a T-25 tissue culture flask, 
and incubated in a humidified 37 °C environment with 5% CO2.  
2.4.4 Guide RNA Design 
Guide RNA were selected using the C. griseus genome (100, 194) and software developed by 
Benchling Inc., CHOPCHOP (195), and CRISPy (196). These programs utilize algorithms (197-199) to 
minimize off-target effects and maximize the likelihood of the gRNA hitting the target site in the 
genome. Only gRNA preceding the canonical PAM, 5’-NGG-3’, were selected. Guide RNA targeting 
earlier exons proximal to the N-terminus side were chosen to minimize the possibility of a partially 
functional protein being translated. The first exon was also avoided to prevent an alternative ATG 
initiation codon from enabling translation of the target protein. Although, gRNA with lengths 
between 16 – 24 base pairs can be effective, only gRNA with a 20 base pair length were chosen 
because research has indicated this length is optimal (200). Finally, all selected gRNA were compared 
directly to the C. griseus genome using the Basic Local Alignment Search Tool (BLAST) to verify each 
gRNA candidate only had a high degree of sequence homology to the target site. For each gene target 







Table 2.1 Sequences of gRNA designed to knockout Gne and Renbp.  











GCTACACACGATCGTTAGAG Gne 2 4388 Sense + GGG 
GTTCGAGTGATGCGGAAGAA Gne 4 12641 Sense + GGG 
CGGCATCTAGAAGCTCAGCG Renbp 3 702 Antisense - AGG 
TGTGCTAGAGAATGTATCAG Renbp 6 2694 Sense + AGG 
 
2.4.5 Cloning the gRNA oligos into the pSpCas9(BB) vector  
The methods for constructing the gRNA-Cas9 plasmid were adapted from previous work (185, 
201, 202). The vector pSpCas9(BB)-2A-GFP (PX458) (Addgene, #48138) was graciously provided by 
Feng Zhang (185). This vector contains the Cas9 from Streptococcus pyogenes along with 2A-EGFP 
(green fluorescent protein) and ampicillin selection markers (Fig. 2.3). Four additional base pairs 
were added to each gRNA oligo and its reverse complement to provide overlap regions with two BbsI 
restriction sites in the pSpCas9(BB)-2A-GFP vector (Table 2.2). The modified gRNA oligos and their 
reverse complements were ordered from Integrated DNA Technologies. The gRNA oligos were 
resuspended in nuclease- and protease-free water to a final concentration of 100 µM. The gRNA 
oligos were combined with the master mix outlined in Table 2.3 and subsequently phosphorylated 
and annealed in a T100 thermocycler (Bio-Rad) using the following parameters: 37 °C for 30 minutes, 
95 °C for 5 minutes, decrease to 25 °C at a rate of 5 °C per minute. The resulting duplex oligos were 
then diluted in nuclease- and protease-free water at a 1:200 ratio. The pSpCas9(BB)-2A-GFP vector 
was digested and the gRNA oligo duplex was ligated into the vector between two BbsI restriction sites 
using the reaction mixture outlined in Table 2.4. The digestion and ligation mixture was incubated 
for 60 minutes using the following cycle repeated six times: 37 °C for 5 minutes, 21 °C for 5 minutes. 
The ligated plasmid was transformed into E. coli strain Stbl3 in a competent state using standard heat 




was added and the E. coli were plated at two different densities on lysogeny broth (LB) plates with 
100 µg mL-1 ampicillin. Untransformed E. coli and E. coli transformed with the linearized but 
unligated plasmid were plated as negative controls. E. coli transformed with the unaltered 
pSpCas9(BB)-2A-GFP vector were plated as a positive control. All plates were incubated for ~24 
hours at 37 °C. The following day plates were inspected for bacterial growth and single colonies were 
selected for expansion via LB liquid cultures supplemented with 100 µg mL-1 ampicillin. Liquid 
bacterial cultures were incubated for ~18 hours at 37 °C with agitation (200 rpm). The following day 
plasmid was isolated from the liquid cultures (2.4.6 Plasmid Isolation) and sent for Sanger 
sequencing to verify correct gRNA insertion. The remaining liquid culture was used to make bacterial 
glycerol stocks for long-term cryogenic storage by combining sterile 50% (v/v) glycerol with the 
bacterial liquid culture in a 1:1 ratio and freezing at -80 °C. Sanger sequencing was performed by the 






Figure 2.3 Vector map of the pSpCas9(BB)-2A-GFP (PX258) plasmid used for knocking out target 
proteins in CHO-K1 cells. The pSpCas9(BB)-2A-GFP is a 9300 base pair vector containing the S. pyogenes Cas9 
gene under the control of the U6 promotor with a CMV enhancer and both GFP and ampicillin genes for 
selection purposes. Guide RNA were cloned between two BbsI restriction sites directly downstream from the 
U6 promotor. The pSpCas9(BB)-2A-GFP was originally designed and constructed by Feng Zhang (185).  
 
 
Table 2.2 Sequences of DNA oligos (sense and anti-sense) cloned into the pSpCas9(BB)-2A-GFP 
(PX258) plasmid. Base pairs in bold text were added to provide overlap between the gRNA and 
destination vector.  
gRNA Sequence (5’ → 3’) gRNA Reverse Complement Sequence (5’ → 3’) 
Gene 
target 
CACCGCTACACACGATCGTTAGAG AAACCTCTAACGATCGTGTGTAGC Gne 
CACCGTTCGAGTGATGCGGAAGAA AAACTTCTTCCGCATCACTCGAAC Gne 
CACCCGGCATCTAGAAGCTCAGCG AAACCGCTGAGCTTCTAGATGCCG Renbp 





Table 2.3 Reaction used to anneal and phosphorylate 
the gRNA oligos.  
Component Volume (µL) 
gRNA (100 µM) 1 
gRNA reverse complement (100 µM) 1 
T4 ligation buffer, 10x 1 
T4 polynucleotide kinase 1 
Nuclease- and protease-free H2O 6 
Total 10 
 
Table 2.4 Reaction used to clone the annealed and 
phosphorylated gRNA oligos into the pSpCas9(BB)-2A-GFP 
(PX258) plasmid.  
Component Volume (µL) 
pSpCas9(BB)-2A-GFP 100 ng 
Diluted oligo duplex  2 
Tango buffer, 10x 2 
DTT, 10 mM 1 
ATP, 10 mM 1 
FastDigest BbsI 1 
T7 ligase 0.5 
Nuclease- and protease-free H2O To 20 µL 
Total 20 
 
2.4.6 Plasmid Isolation  
All plasmids were isolated from bacteria using the QIAprep Spin Miniprep Kit (Qiagen, 27106) 
per the manufacturer’s instructions. To summarize, bacterial liquid cultures were pelleted via 
centrifugation at 6,800 x g for 3 minutes at room temperature. The bacterial pellet was resuspended 
in 250 µL Buffer P1, lysed with 250 µL Buffer P2, and neutralized with 350 µL Buffer N3. This mixture 




QIAprep 2.0 spin column. The sample was processed using a vacuum manifold and washed with 
Buffer PB and Buffer PE. The column then was centrifuged for 1 minute at 17,900 x g to remove 
residual Buffer PE and eluted using nuclease- and protease-free water. The plasmid concentration 
was determined using a Nanodrop 2000 (Thermo Fisher Scientific).  
2.4.7 Transfection 
The day before transfection CHO-K1 cells were seeded in 6-well plates at a density of 1.5 x 106 
cells mL-1. The following day Lipofectamine 2000 (Thermo Fisher Scientific, 11668027) and sequence 
verified pSpCas9(BB)-2A-GFP plasmid with the appropriate gRNA inserted were combined to 
transfect the CHO-K1 cells. For each target protein (i.e. Gne and Renbp) both constructed plasmids 
were used to co-transfect the CHO cells to increase the likelihood of indel generation and protein 
knockout. For each well to be transfected 2500 ng of each plasmid DNA was diluted in 250 µL Opti-
Mem I reduced serum medium and 2.5 µL of Lipofectamine 2000 was diluted in 250 µL Opti-Mem I 
reduced serum medium. The diluted plasmid DNA and Lipofectamine 2000 solutions were combined 
in a 1:1 ratio and incubated at room temperature for 20 minutes to allow for complexation of DNA 
and Lipofectamine. During incubation the spent media from the 6-well plates with CHO-K1 cells was 
aspirated and the cells were washed once with PBS. The wells were replenished with 1.5 mL of F-12K 
media without FBS and antibiotic-antimycotic solution. Once the DNA-Lipofectamine complexes had 
formed 500 µL of the complex was added to each well. DNA plasmid and lipofectamine were also 
individually added to one well each to serve as negative controls. The cells were incubated for 24 
hours at 37 °C in a humidified environment with 5% CO2. After 24 hours the media was aspirated and 
replaced with fresh F-12K media supplemented with 10% (v/v) FBS and 1% (v/v) antibiotic-
antimycotic solution. Forty-eight hours post-transfection the cells were examined for GFP expression 
using an EVOS FL Imaging System (Thermo Fisher Scientific) and harvested for fluorescent activated 




2.4.8 Fluorescent Activated Cell Sorting  
Forty-eight hours post-transfection CHO cells were detached and pelleted as described in the 
2.4.1 Cell Culture section. The pelleted cells were resuspended in 2% (w/v) bovine serum albumin 
(BSA) in Hanks’ buffered salt solution (HBSS) to prevent cell aggregation during the sorting process. 
Cells were sorted using a Becton Dickinson FACS Canto II (3 laser, 8 color) (BD Biosciences).  All FACS 
experiments were performed with the assistance of Hao Zhang in the Johns Hopkins Bloomberg 
School of Public Health Flow Cytometry and Immunology Core facility. Each sample was filtered with 
a sterile 35 µm nylon mesh strainer and combined with 10 µg mL-1 of propidium iodide (PI). Each 
sample was sorted based on the following parameters: morphology, granularity, PI negative, and GFP 
positive. Single sorted cells were then seeded in 96-well plates with 100 µL of F-12K media 
supplemented with 10% (v/v) FBS and 1% (v/v) antibiotic-antimycotic solution in order to obtain 
monoclonal cell lines.  The monoclonal cell lines were supplemented with 50 µL of media every three 
days for a total of 12-14 days. Monoclonal cell lines exhibiting positive growth were expanded to 6-
well plates for downstream analysis and validation of protein knockout.  
2.4.9 Genomic DNA Extraction and Amplification  
Following cell expansion 1 x 105 cells were collected from each monoclonal population for 
genomic DNA (gDNA) extraction and the remaining cells were cryopreserved (2.4.2 Mammalian 
Cell Cryopreservation). Each sample was centrifuged at 1057 x g for 5 minutes, washed once with 
PBS, and resuspended in 50 µL QuickExtract DNA Extraction Solution (Lucigen, QE0950). The gDNA 
was isolated by heating in a T100 thermocycler (Bio-Rad) at 65 °C for 10 minutes followed by 98 °C 
for 5 minutes and then diluted in 100 µL of nuclease- and protease-free water. Primers were designed 
to amplify a 600 – 1000 base pair amplicon with greater than 100 base pairs flanking the CRISPR cut 
site. The primers were designed using Integrated DNA Technologies PrimerQuest Tool using the 




= 22 nucleotides (Table 2.5). Each sample’s isolated gDNA was combined in the reaction mix outlined 
in Table 2.6 and amplified using a T100 thermocycler (Bio-Rad) with the cycle given in Table 2.7. 
The resulting PCR products were analyzed using a 1% (w/v) agarose gel in 1x tris boric 
ethylenediaminetetraacetic acid with 0.5 µg mL-1 ethidium bromide. Each sample was combined with 
5x loading dye and loaded after the gel had solidified. The gel was run at ~120 volts for 60 minutes 
and the products were visualized with ultraviolet light at 300 or 360 nm.  
 
Table 2.5. Primers used to amplify a region of genomic DNA near the Cas9 cut site of each 
gene target.  








GTAACAGTGGGAATCAGGTAGAA Gne Exon 2 23 54.0 43.5 
AGCAAGAGCCGTGAAGTAAA Gne Exon 2 20 54.3 45.0 
ACTGTGGTATCCTACCCTATCC Gne Exon 4 22 55.0 50.0 
CGAACTCCACAGCTGCTATT Gne Exon 4 20 55.0 50.0 
CACTCCCATGACCAGGAATATG Renbp Exon 3 22 55.1 50.0 
GGTGAGGGCTTGGAATATACTG Renbp Exon 3 22 55.1 50.0 
TCTGTGGGCATTCAACTCTATC Renbp Exon 6 22 54.5 45.5 












Table 2.6. PCR used to amplify genomic DNA near the Cas9 cut site 
of each gene target.  
Component Volume (µL) 
Genomic DNA  4 (~40 ng) 
Forward Primer (9 µM stock) 1 (final conc. 300 nM) 
Reverse Primer (9 µM stock) 1 (final conc. 300 nM) 
OneTaq Hot Start 2X Master Mix  15 
Nuclease free H2O  9 (to 30 µL) 
Total 30 
 
Table 2.7. PCR cycle used to amplify genomic DNA near the Cas9 
cut site of each gene target.  
Step Temperature (°C) Time (min:sec) Cycles 
Denature 95 5:00 1 
Denature 95 0:30 
40 Anneal  58 0:30 
Extend 72 0:30 
Extend 72 5:00 1 
Store 4 ∞ NA 
 
2.4.10 PCR Reaction Purification  
If the desired PCR product was the only one observed using gel electrophoresis the remaining 
PCR reaction was purified using a QIAquick PCR Purification Kit (Qiagen, 28104) per the 
manufacturer’s instructions. To briefly summarize, 5 volumes of Buffer PB was added to 1 volume of 
PCR reaction and if the reaction color turned orange or violet, 3 M sodium acetate, pH 5.0 was added. 
The reaction was transferred to a QIAquick column and the DNA was bound to the membrane using 




minute to remove residual buffer, and eluted with nuclease- and protease-free water. The purified 
DNA product concentration was determined using a Nanodrop 2000 (Thermo Fisher Scientific). The 
purified PCR products were submitted for Sanger sequencing (Johns Hopkins School of Medicine 
GRCF) using the corresponding forward and reverse primer pair used to amplify the product.  
2.4.11 Gel Extraction  
If multiple PCR products were observed using gel electrophoresis the target amplicon was 
isolated using the QIAquick Gel extraction Kit (Qiagen, 28115) per the manufacturer’s instructions. 
To summarize, the target DNA fragment was excised from the gel, weighed, and combined with 3 
volumes Buffer QG. The gel buffer mix was incubated at 50 °C for 10 minutes with periodic vortexing; 
if the mixture turned violet or orange, 3 M sodium acetate, pH 5.0 was added. One volume of 2-
propanol was added and each sample was transferred to a QIAquick spin column. The DNA was 
bound to the column membrane using a vacuum manifold, washed once with Buffer QG and Buffer 
PE, and centrifuged at 17,900 x g for 1 minute to remove any residual wash buffer. The DNA was 
eluted from the membrane with nuclease- and protease-free water and the concentration was 
determined using a Nanodrop 2000 (Thermo Fisher Scientific). The purified PCR products were 
submitted for Sanger sequencing (Johns Hopkins School of Medicine GRCF) using the corresponding 
forward and reverse primer pair used to amplify the product.  
2.4.12 TOPO-TA Cloning 
Monoclonal cells lines whose PCR products sequencing results showed indel generation were 
further validated by cloning the PCR amplicon into a pCR 4-TOPO vector using the TOPO TA Cloning 
Kit for Sequencing (Thermo Fisher Scientific, K4575J10). The purified PCR products were ligated to 
the pCR 4-TOPO vector using the reaction mix outlined in Table 2.8 and incubated for 15 minutes at 
room temperature. The ligated plasmid was transformed into Top10 chemically competent E. coli 




incubated at 37 °C for 1 hour at 200 rpm. The transformed E. coli were plated at two different 
densities on LB plates with 100 µg mL-1 ampicillin and incubated for ~24 hours in a 37 °C. The next 
day 10 single colonies were selected per sample and used to inoculate LB liquid cultures 
supplemented with 100 µg mL-1 ampicillin. Liquid bacterial cultures were incubated for ~18 hours 
at 37 °C at 200 rpm. The following day plasmid was isolated from the liquid cultures (2.4.6 Plasmid 
Isolation) and sent for Sanger sequencing (Johns Hopkins School of Medicine GRCF). 
Table 2.8 Reaction mix for TOPO cloning.  
Component Volume (µL) 
Fresh PCR product 0.5 – 4 
Salt solution 1 
Nuclease- and protease- free water add to a total volume of 5 µL 
pCR 4-TOPO vector 1 µL 
Total 6 
 
2.4.13 Western Blotting  
Approximately 1 x 106 cells were harvested (2.3.1 Cell Culture), transferred to a microcentrifuge 
tube, washed once with PBS, and resuspended in 10 – 25 µL of radioimmunoprecipitation assay 
buffer (RIPA) supplemented with protease inhibitor cocktail (Sigma Aldrich, P8340-5ml). The 
samples were incubated on ice for 30 minutes and each sample was vortexed every 10 minutes to 
promote cell lysis. The samples were centrifuged at ~22,000 x g at 4 °C for 15 minutes and the 
resulting supernatant was transferred to a fresh microcentrifuge tube. Each protein sample was 
quantified via the bicinchoninic acid (BCA) assay (203).  To summarize, eight BSA standards ranging 
from 20-20,000 µg mL-1 were made in PBS via serial dilutions and 10 µL were added to a 96-well 
plate in duplicate. One microliter of protein sample was combined with 9 µL PBS and added to the 




prepared per the manufacturer’s instructions and 100 µL was added to each standard and protein 
sample. The 96-well plate was incubated at 37 °C for ~45 minutes and each wells absorbance was 
measured at 562 nm using a Synergy HTX Multi-Mode Microplate Reader (BioTek).  
Fifteen micrograms of each protein sample was combined with 4x laemmli concentrate 
supplemented with 2-mercaptoethanol and diluted to 30 µL with RIPA buffer and protease inhibitor 
cocktail solution. The samples were denatured by heating at 90 °C for 10 minutes and loaded onto a 
Mini-PROTEAN TGX 4-15% gradient gel with a 10-well comb and 30 µL well volume. The gel was run 
in 1x tris/glycine/SDS buffer (Biorad, 161-0772) for ~60 minutes at 100 volts. The protein was 
subsequently transferred to a 0.45 µM nitrocellulose membrane using standard wet transfer 
techniques with all components being equilibrated with 1x tris/glycine buffer (Biorad, 161-0771) 
with 20% (v/v) methanol. The transfer was run in 1x tris/glycine buffer with 20% (v/v) methanol 
on ice at exactly 100 volts for 60 minutes. The membrane was blocked in 5% (w/v) BSA in tris 
buffered saline with 0.1% (v/v) Tween 20 (TBST) at room temperature for 60 minutes with agitation. 
The primary antibodies were diluted in 5% (w/v) BSA in TBST to the recommended concentration 
and added to the blot for overnight incubation at 4 °C with agitation. The primary antibodies used for 
western blots in this chapter and their dilution ratios are listed in Table 2.9. The next day the blot 
was washed three times with TBST for 10 minutes each with agitation. The appropriate horse radish 
peroxidase (HRP) linked secondary antibody (anti-mouse IgG, [Cell Signaling, 7076] or anti-rabbit 
IgG, [Cell Signaling, 7074]) was diluted in 5% (w/v) BSA in TBST at a 1:10,000 ratio, added to the 
blot, and incubated for 60 minutes at room temperature with agitation. After incubation the blot was 
washed three times with TBST for 10 minutes each with agitation. While washing, the enhanced 
chemiluminescent substrate was prepared by combining SuperSignal West Pico PLUS 
Luminol/Enhancer solution (Thermo Fisher Scientific, 1863098) with SuperSignal West Pico PLUS 
Stable Peroxidase solution (Thermo Fisher Scientific, 1863099) in a 1:1 ratio. After the third TBST 




transferred to a plastic sheet protector in a film cassette for imaging using Blu-C autoradiography 
films (Stellar Scientific, BLC-810-100).  
After imaging the blot was stripped for 15 minutes using Gentle Review Stripping Buffer 
(Amresco, A611-N552-13), washed three times with TBST for 10 minutes each and reblocked with 
5% (w/v) BSA in TBST for 60 minutes at room temperature with agitation. As a loading control, 
 actin (Cell Signaling, 3700) diluted in 5% (w/v) BSA in TBST at a 1:10,000 ratio was added to the 
blot and incubated at room temperature for 30 minutes with agitation. The blot was washed three 
times with TBST for 10 minutes each and HRP-linked anti-mouse IgG diluted 1:10,000 in 5% (w/v) 
BSA in TBST was added to the blot for 30 minutes. The blot was washed three times with TBST for 
10 minutes and imaged via autoradiography as described above. Western blotting to assess protein 
level knockouts of Gne and Renbp were repeated in biological triplicate for each cell line.  
Table 2.9 Primary antibodies used to assess protein level knockout of Gne and Renbp.  








PA5-55559 0.4 µg mL-1 (1:250) 
Anti-RENBP 
antibody 
Renbp Abcam ab77081 0.7 µg mL-1 (1:1000) 
 
2.4.14 Densitometry 
ImageJ (National Institute of Health) was used to compare and quantify the density (intensity) of 
the bands for each western blot sample. Gel images were saved as TIFF files, opened in ImageJ, and 
converted to an 8-bit gray-scale image (Image→Type→8-bit). The rectangle tool was used to select 
the first lane and it was defined as lane 1 by selecting Analyze→Gels→Select First Lane. The first 
rectangle was copied and dragged to surround the second lane and it was defined as lane 2 by 




all lanes were selected the intensity was analyzed by selecting Analyze→Gels→Plot. The output 
profile plot represents the relative density of the rectangle surrounding each lane. The line tool was 
used to enclose the peak at the baseline to eliminate background signal. The size of each peak was 
quantified by using the Wand tool to highlight each peak. The peaks were labeled with their size as a 
percentage relative to the total size of all peaks by selecting Analyze→Gels→Label Peaks. The density 
of each peak was then expressed relative to the peak intensity for the wild type CHO sample and 
adjusted based on the peak intensity of the  actin loading control.   
2.4.15 ManNAx Chemical Analog Synthesis 
The 1,3,4-O-Bu3ManNAc and 1,3,4-O-Bu3ManNAz analogs used throughout this chapter were 
synthesized as described in previous work (156). The chemical analogs used in these experiments 
were synthesized and characterized by Christian Agatemor and Chris Saeui.  
2.4.16 Periodate Resorcinol Assay 
Forty-eight hours before performing the periodate resorcinol assay 1.5 x 106 cells were seeded 
in 100 mm x 20 mm tissue culture dishes using F-12K nutrient mixture supplemented with 10% (v/v) 
FBS and 1% (v/v) antibiotic-antimycotic solution. Twenty-four hours before performing the assay 
the cells were treated with 1,3,4-O-Bu3ManNAc to final concentrations of 100 µM, 300 µM, and 500 
µM. Untreated controls were given a volume of 200 proof ethanol (the solvent vehicle) equivalent to 
the highest treatment group (i.e. 500 µM). The analogs were resuspended in F-12K nutrient mixture 
supplemented with 1% (v/v) FBS and no antibiotics and added to the corresponding culture dishes. 
Free intracellular sialic acid levels were quantified using the previously developed periodate 
resorcinol assay adapted to a 96-well plate format using an 10-point standard curve (132, 204). The 
treated cells were harvested by aspirating the media, washing three times with PBS, and detaching 
nonenzymatically using CellStripper Dissociation Reagent (Corning, 25056CI). Cell density of each 




Coulter) and normalized such that each sample contained 2.5 x 106 cells. The samples were 
centrifuged at 3000 x g for 3 minutes, resuspended in 300 µL of PBS, and lysed by freeze-thawing 
three times using liquid nitrogen. The cell lysates and sialic acid standards (0 – 250 µM) were 
oxidized with 0.4 M periodic acid and cooled on ice for 10 minutes. A resorcinol mixture containing 
10% (v/v) 0.5 M resorcinol, 10% (v/v) 2.5 mM CuSO4, 44% (v/v) concentrated HCl, and 36% (v/v) 
MilliQ water was prepared. After oxidation, 500 µL of the resorcinol mixture was added to each 
sample and the samples were heated at 100 °C for 10 minutes. After heating, the samples were cooled 
on ice and 500 µL of tert-butyl was added to each sample to stop the reaction. The samples were 
centrifuged for two minutes at 16000 x g and 100 µL of each was added to a 96-well plate in triplicate. 
The absorbance was measured at 630 nm using a Synergy HTX Multi-Mode Microplate Reader 
(BioTek). Free intracellular sialic acid levels were then determined by creating a standard curve and 
expressed as molecules of sialic acid per cell.  
2.4.17 Azide Incorporation Flow Cytometry Assay 
Forty-eight hours before performing the assay 1.5 x 105 cells mL-1 of each sample were seeded in 
6-well plates using F-12K nutrient mixture supplemented with 10% (v/v) FBS and 1% (v/v) 
antibiotic-antimycotic solution. Twenty-four hours before the assay was performed the cells were 
treated with 1,3,4-O-Bu3ManNAz to final concentrations of 100 µM, 200 µM, and 300 µM. Untreated 
controls were given a volume of 200 proof ethanol (the solvent vehicle) equivalent to the highest 
treatment group (i.e. 300 µM). The analogs were resuspended in F-12K nutrient mixture 
supplemented with 1% (v/v) FBS and no antibiotics and added to the corresponding wells. 
Approximately twenty-four hours post-treatment the media was aspirated and each well was washed 
three time with PBS. Dibenzocyclooctyne-Cy5 (DBCO-Cy5) (Sigma-Aldrich, 777374) was 
resuspended in DMSO to a stock concentration of 1 mg mL-1 which was in turn diluted to a final 




protected from light for all subsequent steps to prevent fluorophore photobleaching. One milliliter of 
the diluted DBCO-Cy5 solution was added to each well of the 6-well plate and incubated at 37 °C for 
30 minutes. The DBCO-Cy5 can react with azide groups in a strain-promoted copper-free azide-
alkyne cycloaddition reaction. After incubation, the DBCO-Cy5 solution was aspirated and each well 
was washed three times with PBS. Following the final wash 300 µL of trypsin-EDTA was added to 
each well and incubated at 37 °C for 3 minutes. PBS was added to each well and the cells were 
transferred to microcentrifuge tubes. The cells were pelleted via centrifugation at 376 x g for 5 
minutes and resuspended in 200 µL of sterile filtered (0.22 µm) 2% (w/v) BSA in HBSS. 
Approximately 100 µL of each sample was transferred to a clear V-bottom 96-well culture plate and 
Cy5 signal was measured using a CytoFLEX flow cytometer (Beckman Coulter). The azide 
incorporation assay was performed in biological triplicate for each cell line.  
2.4.18 Azide Incorporation Plate Reading Assay 
Forty-eight hours before performing the assay 1.5 x 105 cells mL-1 of each sample were seeded in 
6-well plates using F-12K nutrient mixture supplemented with 10% (v/v) FBS and 1% (v/v) 
antibiotic-antimycotic solution. Twenty-four hours before the assay was performed the cells were 
treated with 1,3,4-O-Bu3ManNAz to final concentrations of 100 µM, 200 µM, and 300 µM. Untreated 
controls were given a volume of 200 proof ethanol (the solvent vehicle) equivalent to the highest 
treatment group (i.e. 300 µM). The analogs were resuspended in F-12K nutrient mixture 
supplemented with 1% (v/v) FBS and no antibiotics and added to the corresponding culture dishes. 
Twenty-four hours post-treatment the cells were washed three times with PBS and 1 mL of 16.5 µM 
DBCO-Cy5 solution was added to each well (prepared as described in 2.4.17 Azide Incorporation 
Flow Cytometry Assay). The cells were incubated with DBCO-Cy5 at 37 °C for 30 minutes. After 
incubation each sample was washed three times with PBS and detached by treating with trypsin-
EDTA solution for 3 minutes at 37 °C. Each sample was transferred to a microcentrifuge tube and 




in 100 µL of PBS, and transferred to a black flat bottom 96-well plate. Cy5 fluorescence was measured 
using a Synergy HTX Multi-Mode Microplate Reader (BioTek) and each measurement was 
normalized based on cell number per sample. The plate reading assay was performed in biological 
triplicate for each sample.  
2.4.19 Live-Cell Imaging of Azide-Labeled Glycans  
Forty-eight hours before performing the assay 1.5 x 105 cells mL-1 of each sample were seeded in 
6-well plates using F-12K nutrient mixture supplemented with 10% (v/v) FBS and 1% (v/v) 
antibiotic-antimycotic solution. Twenty-four hours before the assay was performed the cells were 
treated with 1,3,4-O-Bu3ManNAz to final concentrations of 100 µM, 200 µM, and 300 µM. Untreated 
controls were given a volume of 200 proof ethanol (the solvent vehicle) equivalent to the highest 
treatment group (i.e. 300 µM). The analogs were resuspended in F-12K nutrient mixture 
supplemented with 1% (v/v) FBS and no antibiotics and added to the corresponding wells. Twenty-
four hours post-treatment the media was aspirated and the cells were washed three times with PBS. 
Alexa Fluor 488 DBCO (AF-DBCO) (Click Chemistry Tools, 1278-1) was resuspended in DMSO to a 
stock concentration of 1 mg mL-1 which was in turn diluted to a working concentration of 25 µM in 
F-12K media without FBS or antibiotics. After the final PBS wash, one milliliter of AF-DBCO solution 
was added to each well and incubated at 37 °C for 30 minutes. Each sample was washed three times 
with PBS and imaged using an EVOS FL Imaging System (Thermo Fisher Scientific).  
2.5 Results & Discussion  
2.5.1 Construction of gRNA-pSpCas9(BB)-2A-GFP Plasmids 
For each protein target (i.e. Gne and Renbp) two gRNA were designed in the event one did not 
efficiently home Cas9 to the genomic target region (Table 2.1). Each gRNA sequence was modified 
to contain four base pairs of overlap with the pSpCas9(BB)-2A-GFP vector and was cloned into the 




efficiency with between 10 – 25 colonies for each construct. Multiple colonies were selected for 
plasmid isolation and Sanger sequencing to verify correct gRNA insertion in the pSpCas9(BB)-2A-
GFP vector. Correct gRNA insertion was verified using the Multiple Sequence Alignment tool 
(MUSCLE). Sanger sequencing indicated the gRNA targeting exon 2 of Gne and the gRNA targeting 
exon 4 of Gne were successfully cloned into the pSpCas9(BB)-2A-GFP vector. The sequencing results 
for both Gne gRNA plasmids had quality scores greater than 20 for the gRNA insertion region 
indicating greater than 99% probability the inferred base pair is correct (Fig. 2.4) (Fig. 2.5). 
Similarly, the Sanger sequencing results indicated the gRNA targeting exon 3 of Renbp and the gRNA 
targeting exon 6 of Renbp were successfully cloned into the pSpCas9(BB)-2A-GFP vector. The 
sequencing results for both Renbp gRNA had quality scores greater than 30 for the gRNA insertion 
region indicating greater than 99.9% probability the inferred base pair is correct (Fig. 2.6) (Fig. 2.7). 
These cloning results corroborate and demonstrate the reproducibility of the cloning methods 







Figure 2.4 Sequencing data for cloning the gRNA targeting Gne exon 2 into the pSpcas9(BB)-2A-GFP 
plasmid. (A) The top panel shows the read quality for each nucleotide from the Sanger sequencing run. (B) The 
middle panel shows the chromatogram for the region where the gRNA was inserted into the pSpCas9(BB)-2A-
GFP vector (gRNA sequence boxed in red). All nucleotides in and immediately surrounding the insertion region 
had quality scores exceeding 20 meaning there is at least a 99% probability the inferred base pair is correct. 
(C) The bottom panel shows the MUSCLE alignment between the unaltered pSpCas9(BB)-2A-GFP vector and 






Figure 2.5 Sequencing data for cloning the gRNA targeting Gne exon 4 into the pSpcas9(BB)-2A-GFP 
plasmid. (A) The top panel shows the read quality for each nucleotide from the Sanger sequencing run. (B) The 
middle panel shows the chromatogram for the region where the gRNA was inserted into the pSpCas9(BB)-2A-
GFP vector (gRNA sequence boxed in red). All nucleotides in and immediately surrounding the insertion region 
had quality scores exceeding 30 meaning there is at least a 99.9% probability the inferred base pair is correct. 
(C) The bottom panel shows the MUSCLE alignment between the unaltered pSpCas9(BB)-2A-GFP vector and 







Figure 2.6 Sequencing data for cloning the gRNA targeting Renbp exon 3 into the pSpcas9(BB)-2A-GFP 
plasmid. (A) The top panel shows the read quality for each nucleotide from the Sanger sequencing run. (B) The 
middle panel shows the chromatogram for the region where the gRNA was inserted into the pSpCas9(BB)-2A-
GFP vector (gRNA sequence boxed in red). All nucleotides in and immediately surrounding the insertion region 
had quality scores exceeding 30 meaning there is at least a 99.9% probability the inferred base pair is correct. 
(C) The bottom panel shows the MUSCLE alignment between the unaltered pSpCas9(BB)-2A-GFP vector and 






Figure 2.7 Sequencing data for cloning the gRNA targeting Renbp exon 6 into the pSpcas9(BB)-2A-GFP 
plasmid. (A) The top panel shows the read quality for each nucleotide from the Sanger sequencing run. (B) The 
middle panel shows the chromatogram for the region where the gRNA was inserted into the pSpCas9(BB)-2A-
GFP vector (gRNA sequence boxed in red). All nucleotides in and immediately surrounding the insertion region 
had quality scores exceeding 30 meaning there is at least a 99.9% probability the inferred base pair is correct. 
(C) The bottom panel shows the MUSCLE alignment between the unaltered pSpCas9(BB)-2A-GFP vector and 
the plasmid with the gRNA sequence inserted (highlighted in yellow).  
 
2.5.2 Transfection 
CHO-K1 cells were transfected with the pSpCas9(BB)-2A-GFP plasmids with gRNA inserts in 
order to knockout Gne and Renbp. A co-transfection strategy utilizing both of the pSpCas9(BB)-2A-
GFP plasmids with gRNA targeting Gne or Renbp was chosen to increase the probability of knocking 
out the target protein if one gRNA proves ineffective. Forty-eight hours post-transfection each sample 
was imaged using fluorescence microscopy to verify GFP expression. The sample that was transfected 
with both Gne targeting plasmids (i.e. gRNA targeting exon 2 and 4 of Gne) and Lipofectamine 2000 




or only the Gne targeting plasmids showed no GFP expression (Fig. 2.8). The sample that was 
transfected with both Renbp targeting plasmids (i.e. gRNA targeting exon 3 and 6 of Renbp) and 
Lipofectamine 2000 showed robust GFP expression while control samples treated with either only 
Lipofectamine 2000 or only the Renbp targeting plasmids showed no GFP expression (Fig. 2.9).  
Once a CHO-K1 cell line with Gne knocked out (CHO-Gne) was engineered and validated the CHO-
Gne cell line was transfected with both Renbp targeting plasmids in order to create a CHO-K1 cell line 
with both Gne and Renbp knocked out (CHO-Gne/-Renbp). Again, forty-eight hours post-transfection this 
sample was imaged using fluorescence microscopy to verify GFP expression. The CHO-Gne sample that 
was transfected with both Renbp targeting plasmids and Lipofectamine 2000 exhibited GFP 
expression while control samples treated with either only Lipofectamine 2000 or only the Renbp 
targeting plasmids showed no GFP expression (Fig. 2.10). Utilization of GFP as a marker for gene 
expression is a common technique that was originally pioneered by Chalfie et al. (205). In all cases 
the fluorescence microscopy images obtained following transfection with Lipofectamine indicate 
strong GFP expression due to uptake of the pSpCas9(BB)-2A-GFP vector. Furthermore, GFP 
expression implies concurrent expression of the gRNA-Cas9 complex also coded on the pSpCas9(BB)-





Figure 2.8 Transmitted light and fluorescence microscopy images of wild type CHO-K1 cells 48 hours 
after transfection with the pSpCas9(BB)-2A-GFP plasmids with gRNA inserts targeting Gne. (A) Wild type 
CHO-K1 cells were transfected with Lipofectamine 2000 and both pSpCas9(BB)-2A-GFP plasmids with gRNA 
inserts targeting exons 2 and 4 in Gne. Wild type CHO-K1 cells were also transfected with (B) Lipofectamine 






Figure 2.9 Transmitted light and fluorescence microscopy images of wild type CHO-K1 cells 48 hours 
after transfection with the pSpCas9(BB)-2A-GFP plasmids with gRNA inserts targeting Renbp. (A) Wild 
type CHO-K1 cells were transfected with Lipofectamine 2000 and both pSpCas9(BB)-2A-GFP plasmids with 
gRNA inserts targeting exons 3 and 6 in Renbp. Wild type CHO-K1 cells were also transfected with (B) 







Figure 2.10 Transmitted light and fluorescence microscopy images of CHO-Gne cells 48 hours after 
transfection with the pSpCas9(BB)-2A-GFP plasmids with gRNA inserts targeting Renbp. (A) CHO-Gne 
were transfected with Lipofectamine 2000 and both pSpCas9(BB)-2A-GFP plasmids with gRNA inserts 
targeting exons 3 and 6 in Renbp. CHO-Gne cells were also transfected with (B) Lipofectamine 2000 alone and 





2.5.3 Fluorescent Activated Cell Sorting  
Forty-eight hours post-transfection the CHO-K1 cells were harvested for FACS in order to isolate 
monoclonal cell populations with either Gne, Renbp, or both proteins knocked out. Each sample was 
gated based on multiple parameters to ensure viable, GFP positive, single cells were seeded. Cells 
with the correct morphology and size were selected by measuring forward-scattered light (FSC) 
pulse height and side-scattered light (SSC) pulse height; for all samples at least 90% of the cells 
exhibited the correct morphology characteristic of CHO-K1 cells. Singlet cells were selected by 
measuring SSC pulse width and height and gating accordingly. Again, in all cases greater than 90% of 
cells in each sample were singlets. Viable cells were selected by staining with PI since it is not 
permeant to live cells and for all samples greater than 99% were PI negative. Finally, cells expressing 
GFP were selected be measuring excitation/emission at 488 nm/510 nm and sorting accordingly. 
Depending on the sample the percentage of each cell population strongly expressing GFP varied 
between 1.30% to 1.48% (Fig. 2.11). The flow cytometry results provide additional confirmation of 
GFP expression in transfected samples. All samples had a relatively low transfection efficiency, 
however, in this case the variation is unproblematic because each sample contained a sufficient 





Figure 2.11 FACS data for sorting CHO cells transfected with gRNA-Cas9 plasmids. All samples were sorted 
and gated based on morphology, granularity, PI negative, and GFP positive. (A) PI and GFP histograms for 
CHOWT cells co-transfected with the gRNA-Cas9 plasmids targeting exon 2 and exon 4 of Gne. (B) PI and GFP 
histograms for CHOWT cells co-transfected with the gRNA-Cas9 plasmids targeting exon 3 and exon 6 of Renbp. 
(C) PI and GFP histograms CHO-Gne cells co-transfected with the gRNA-Cas9 plasmids targeting exon 3 and exon 





2.5.4 Genetic Analysis of Indel Generation 
After single cells of each sample were sorted and seeded each monoclonal cell line was grown for 
10 – 14 days before expansion to 6-well plates and subsequent genetic analysis. In order to analyze 
potential indel generation in each monoclonal population a 600 – 1000 base pair region of the 
genomic DNA containing the gRNA cut site was amplified. Gel electrophoresis was used to verify 
successful amplification of the target genomic DNA sequence. Each amplicon was isolated and 
directly Sanger sequenced to give a preliminary indication of indel generation in each monoclonal 
cell population (data not shown). Of the amplicons sequenced a variety of different indels were found 
including base pair insertions, deletions, and a mix of both. In all cases the genomic edits occurred 
between 3-5 base pairs upstream of the PAM motif indicating the edits were made by Cas9 double 
stranded breaks. Of these samples, monoclonal cell populations with indels resulting in frame shifts 
were selected for more rigorous genetic analysis. Of the wild type CHO cell lines (CHOWT) transfected 
with the Gne targeting CRISPR plasmids a monoclonal population with a one base pair deletion on 
exon 2 and a one base pair insertion on exon 4 was selected (CHO-Gne). Of the wild type CHO cell lines 
transfected with the Renbp targeting CRISPR plasmids a monoclonal population with a one base pair 
insertion on exon 3 and a one base pair insertion on exon 6 was selected (CHO-Renbp). Of the CHO-Gne 
cell lines transfected with the Renbp targeting CRISPR plasmids a monoclonal population with a one 
base pair insertion on exon 3 and a one base pair insertion on exon 6 was selected (CHO-Gne/-Renbp). 
For all samples the nucleotides within and directly surrounding the edited site had quality scores 
greater than or equal to 20 indicating greater than 99% probability the inferred base pair is correct.  
The CHO-Gne, CHO-Renbp, and CHO-Gne/-Renbp cell lines were further validated by cloning the genomic 
DNA amplicons into an empty vector via TOPO cloning. For each edited genomic site, plasmid was 
isolated from 10 bacteria colonies and Sanger sequenced. All 10 plasmids with the amplicon insert 
derived from exon 2 of the CHO-Gne cell line showed deletion of a thymine residue five base pairs 




10 plasmids with the amplicon insert derived from exon 4 of the CHO-Gne cell line showed insertion 
of one adenine nucleotide five base pairs upstream of the PAM motif implying a homozygous gene 
edit (Fig. 2.12). For the plasmids with an amplicon insert from exon 3 of the CHO-Renbp cell line nine 
showed an insertion of one thymine residue while one plasmid had an insertion of a cytosine residue 
in the same location. The inserted thymine and cytosine residues had sequencing quality scores 
greater than 20 suggesting that this monoclonal cell line may have a heterozygous gene edit (Fig. 
2.13). Similarly, for the plasmids with an amplicon insert from exon 6 of the CHO-Renbp cell line nine 
exhibited insertion of one thymine residue while the remaining plasmid showed insertion of a 
cytosine residue at the same location. Since the quality scores exceeded 20 for all inserted residues 
this again suggests the gene mutation at this location is heterozygous (Fig. 2.13). Interestingly, the 
10 plasmids with inserts from exon 3 and exon 6 of Renbp derived from the CHO-Gne/-Renbp line 
exclusively showed a thymine insertion 3 and 4 nucleotides away from the PAM motif, respectively 
(Fig. 2.14). This is a strong indication of homozygous gene edits at both locations and demonstrates 
that even when using the same gRNA the homo- or heterozygous nature of the gene edit can vary 
depending on the monoclonal cell line.  Overall, this sequencing data provides strong evidence that 
Gne and Renbp were successfully knocked out in CHO cells, however more rigorous genetic analysis 







            
Figure 2.12 Genetic analysis of indel generation in CHO-Gne cells. The region on exon 2 and exon 4 of Gne targeted by the gRNA was amplified and 
cloned into an empty vector. Plasmid was isolated from 20 bacteria colonies (10 per gRNA target site) and Sanger sequenced. (A) For the exon 2 site, all 
plasmids showed deletion of one thymine residue five base pairs upstream of the PAM motif. (B) For the exon 4 site, all plasmids showed insertion of one 
adenine residue five base pairs upstream of the PAM motif. The quality score graph and chromatogram are shown for one representative plasmid for each 
target site and the MUSCLE alignment of all plasmids with Gne is show on the bottom. The gRNA is highlighted in yellow, the PAM sequence is highlighted 






          
Figure 2.13 Genetic analysis of indel generation in CHO-Renbp cells. The region on exon 3 and exon 6 of Renbp targeted by the gRNA was amplified and 
cloned into an empty vector. Plasmid was isolated from 20 bacteria colonies (10 per gRNA target site) and Sanger sequenced. (A) For the exon 3 site, nine 
plasmids showed insertion of one thymine residue while one plasmid showed insertion of a cytosine residue at the same location. (B) For the exon 6 site, 
nine plasmids showed insertion of one thymine residue, while one plasmid showed insertion of a cytosine residue at the same location. The quality score 
graph and chromatogram are shown for one representative plasmid for each target site and the MUSCLE alignment of all plasmids with Renbp is show on 








         
Figure 2.14 Genetic analysis of indel generation in CHO-Gne/-Renbp cells. The region on exon 3 and exon 6 of Renbp targeted by the gRNA was amplified 
and cloned into an empty vector. Plasmid was isolated from 20 bacteria colonies (10 per gRNA target site) and Sanger sequenced. (A) For the exon 3 site, 
all plasmids showed insertion of one thymine residue three base pairs after the PAM motif. (B) For the exon 6 site, all plasmids showed insertion of one 
thymine residue four base pairs upstream of the PAM motif. The quality score graph and chromatogram are shown for one representative plasmid for 
each target site and the MUSCLE alignment of all plasmids with Renbp is show on the bottom. The gRNA is highlighted in yellow, the PAM sequence is 
highlighted in green and the gene edit is highlighted in red
 
2.5.5 Protein Level Knockout Validation  
In order to validate the sequencing data and to verify protein level knockout of the target protein 
immunoblotting was performed. Protein extracted from each sample was probed with a polyclonal 
GNE antibody (Thermo Fisher Scientific, PA5-55559) at a concentration of 0.4 µg mL-1. Both the CHO-
Gne and CHO-Gne/-Renbp cell lines lacked a band at ~74 kDa while the CHOWT and CHO-Renbp cell lines 
showed a robust band at this location (Fig. 2.15). The intensity of each band was quantified and 
expressed relative to the CHOWT signal and adjusted based on the corresponding  actin loading 
control (Fig. 2.16A). Both the bands for CHO-Gne and CHO-Gne/-Renbp gave an average density less than 
0.01 relative to CHOWT and were significantly less than the CHO-Rnebp cells (p<0.001) suggesting that 
no signal was present for these samples. The small basal signal can likely be attributed to background 
and nonspecific signal. The CHO-Renbp bands yielded an average density of ~1.2 suggesting that this 
cell line may have higher Gne expression relative to CHOWT, however it is more likely this difference 
is simply variation in the western blotting process.  
Similarly, protein extracted from each sample was probed with a polyclonal RENBP antibody 
(Abcam, ab77081) at a concentration of 0.7 µg mL-1. Surprisingly, visible bands around 52 kDa were 
seen for all cell lines even those with sequencing data that had indicated that Renbp was knocked out 
(Fig. 2.15). Again, the intensity of each band was quantified and expressed relative to the CHOWT 
signal and adjusted based on the corresponding  actin loading control (Fig. 2.16B). The CHO-Renbp 
and CHO-Gne/-Renbp cell lines both had an average density slightly less than one relative to CHOWT, which 
could indicate a partial knockdown of Renbp in these cell lines. However, because the standard error 
of means is large for all samples it is more likely this difference is due to slight variations in the 
western blotting and densitometry analysis process. Additionally, the band intensities of CHO-Renbp 
and CHO-Gne/-Renbp were not significantly different from the CHO-Gne band intensity. The presence of a 
band for the Renbp knockout cell lines could be due to several reasons. First, it is possible that Renbp 




mediated gene edits. However, if this was the case it would be expected that the bands for the Renbp 
knockout lines would at least have a more pronounced reduction in signal relative to the wild type 
cells. Another possible explanation is Renbp has a long half-life, yet no reduction in signal was 
observed even after multiple (>5) passages of the cell lines.  Another possibility is a partial, 
nonfunctional version of Renbp is still being translated which the antibody is capable of binding to, 
thus yielding a signal during immunoblotting. However, this is unlikely because the observed band is 
at the expected size of 52 kDa, whereas a partial version of Renbp would be expected to give a signal 
at a lower molecular weight. A final explanation is the antibody used to probe for Renbp is 
nonspecifically binding to another protein of similar molecular weight. This could be because the 
antibody was designed to bind human RENBP and although human and C. griseus have considerable 
genomic homology some variations do exist. Taking into account the sequencing and immunoblotting 
data it is probable Renbp was successfully knocked out, however more rigorous screening will be 
needed to fully validate the knockout.  
 
Figure 2.15 Representative western blot analysis of protein level knockout of 
Gne and Renbp in CHO cells. The engineered cells lines CHO-Gne, CHO-Renbp, and 
CHO-Gne/-Renbp with sequence verified indel generation were probed for protein level 
expression of Gne and Renbp. Western blot analysis was repeated in biological 






Figure 2.16 Densitometry quantification of western blot band intensities. ImageJ was used to measure 
band intensity. Each measurement was adjusted based on the  actin loading control and expressed as density 
relative the CHOWT signal. (A) When the samples were probed for Gne both CHO-Gne and CHO-Gne/Renbp yielded a 
band intensity less than 0.01 relative to CHOWT while the CHO-Renbp band intensity was ~1.2 relative to CHOWT. 
The band intensity of CHO-Gne and CHO-Gne/-Renbp was significantly less than the CHO-Renbp intensity (p<0.001) 
(indicated by *) (B) When samples were probed for Renbp all three engineered cell lines yielded band 
intensities approximately equal to 1 relative the CHOWT. Error bars represent the standard error of the mean 
between three independent biological replicates.  
 
2.5.6 Periodate Resorcinol Assay 
The periodate resorcinol assay was used to quantify differences in free intracellular sialic acid 
levels between the engineered cell lines when treated with varying concentrations of 1,3,4-O-
Bu3ManNAc. Equal amounts of each of the three engineered CHO lines (i.e. CHO-Gne, CHO-Renbp, CHO-
Gne/-Renbp) and the wild type CHO line were tested at concentrations of 0 µM, 100 µM, 300 µM, and 500 
µM of 1,3,4-O-Bu3ManNAc. Three biological replicates were performed for each of the 16 samples 
(Fig. 2.17).  For all cell lines the level of free intracellular sialic acid increased in a concentration-
dependent manner upon supplementation with 1,3,4-O-Bu3ManNAc. The largest increase in sialic 
acid production occurred between 0 and 100 µM 1,3,4-O-Bu3ManNAc for all of the cell lines with 
further smaller and cell-line-dependent increases observed at 300 and 500 µM. These trends are in 




1,3,4-O-Bu3ManNAc increases flux through the SABP leading to increased sialylation levels (156, 157, 
159).  
Both the CHO-Gne and CHO-Gne/-Renbp cell lines had noticeably lower levels of free intracellular sialic 
acid at all concentrations of 1,3,4-O-Bu3ManNAc. This difference is unsurprising considering that in 
addition to the epimerization of UDP-GlcNAc to ManNAc, Gne also subsequently phosphorylates this 
monosaccharide to ManNAc-6-phosphate. Importantly, unlike the first epimerization step, the 
phosphorylation step is not compensated by the addition of exogenous ManNAc. Nevertheless, even 
in the absence of Gne, sialylation levels were able to increase more than 7-fold when treated with an 
external source of ManNAc (i.e. 1,3,4-O-Bu3ManNAc). The levels of sialic acid in any of the 1,3,4-O-
Bu3ManNAc-treated cells, in fact, were higher than in the non-supplemented CHOWT line. This result 
indicates nonspecific kinases exist that can phosphorylate ManNAc in the absence of Gne, albeit less 
efficiently. Specifically, GlcNAc kinase may be able phosphorylate ManNAc in the absence of Gne 
(189).  GlcNAc kinase has a millimolar Km for ManNAc while a micromolar Km for GlcNAc (its natural 
substrate) meaning it could phosphorylate ManNAc obtained from non-Gne sources which would 
explain the low but nonzero levels of sialylation in untreated cells lacking Gne. Then supplementation 
with 1,3,4-O-Bu3ManNAc could lead to an increase in the reaction velocity of GlcNAc kinase catalyzed 
phosphorylation of ManNAc resulting in the observed increase in sialylation levels. In theory, to reach 
the measured ~1 x 1010 sialic acid molecules per cell for CHO-Gne and CHO-Gne/-Renbp lines would require 
an internal ManNAc concentration of ~166 mM assuming a cell volume of 1 pL. This number might 
even understate the actual requisite internal ManNAc concentration because it assumes perfect 
conversion of ManNAc to sialic acid without any diversion to other biochemical pathways. Critically, 
this level of intracellular ManNAc is within the millimolar Km of GlcNAc kinase suggesting from an 
enzymatic kinetics standpoint it could phosphorylate ManNAc in the absence of Gne.  GlcNAc kinase 
offers one possible explanation for the basal sialylation measured even in the absence of Gne; 




acid lyase or an artifact from using serum in the cell culture media or even background signal (192, 
206).  
Knocking out Renbp appeared to have little to no effect on free intracellular sialic acid levels in 
both treated and untreated cells. In both the CHOWT and CHO-Renbp cell lines sialylation increased in a 
concentration-dependent manner upon supplementation with 1,3,4-O-Bu3ManNAc, but was not 
significantly different at any treatment level. This result was expected because the Renbp catalyzed 
interconversion of ManNac and GlcNAc is a secondary source of ManNAc, and GlcNAc is the 
thermodynamically favored product. The CHO-Gne and CHO-Gne/-Renbp cell lines had lower sialylation 
levels (relative to CHOWT and CHO-Renbp) that increased in a concentration-dependent manner 
following treatment with 1,3,4-O-Bu3ManNAc, but did not significantly differ at any treatment level. 
This result was also expected because in the absence of Gne GlcNAc levels will increase which will 
increase the GlcNAc to ManNAc ratio pushing the reaction toward ManNAc production. 
Supplementing these cells with an exogenous ManNAc source will in turn lower the GlcNAc to 
ManNAc ratio which could push the equilibrium back toward GlcNAc production. The results of this 
experiment suggest that the build-up of GlcNAc outweighs the exogenous supply of ManNAc pushing 
the reaction toward ManNAc production. However, a previous study showed that when wild type 
Jurkat cells and Jurkat cells lacking Renbp were treated with 10 mM ManNAc the cells lacking Renbp 
produced less sialic acid (191). These two possible mechanisms are not necessarily mutually 
exclusive and will depend on the dynamic changes in GlcNAc and ManNAc levels. Alternatively, the 
discrepancies between that study and these experiments could be due to inherent variations between 
Jurkat and CHO cells. Another feasible explanation is the CRISPR-Cas9 methodology failed to 
completely knockout Renbp (even if genomic analysis suggests otherwise) thus resulting in the 








Figure 2.17 Comparison of free intracellular sialic acid levels in various engineered CHO cell lines 
treated with 1,3,4-O-Bu3ManNAc grouped by analog concentration (A) and cell line (B). CHOWT, CHO-Gne, 
CHO-Renbp, and CHO-Gne/-Renbp cell lines were treated with various concentrations of 1,3,4-O-Bu3ManNAc (100 µM, 
300 µM, 500 µM) or an equivalent volume of the solvent vehicle, ethanol. Twenty-four hours post-treatment 
2.5 x 106 cells were used to determine free intracellular sialic acid levels using the periodate resorcinol method. 




2.5.7 Azide Incorporation Flow Cytometry Assay 
Flow cytometry was used in order to measure the ability of the different engineered cell lines 
(CHOWT, CHO-Gne, CHO-Renbp, CHO-Gne/-Renbp) to incorporate 1,3,4-O-Bu3ManNAz into cellular 
glycosylation. Flow Cytometry was used to quantify azide incorporation after incubating treated and 
untreated cells with the cyclooctyne, DBCO, conjugated to the fluorophore Cy5. DBCO-Cy5 can react 
with azide moieties in a strain-promoted copper-free azide-alkyne cycloaddition reaction at 
physiological conditions (Fig. 2.18) (207). All cells lines treated with the solvent vehicle (ethanol) 
exhibited similar basal Cy5 fluorescence levels. When each cell line was treated with 1,3,4-O-
Bu3ManNAz mean fluorescence intensity (MFI) increased by approximately two orders of magnitude 
relative to untreated samples. There were minimal differences in MFI between each cell line and MFI 
did not increase with concentration of 1,3,4-O-Bu3ManNAz indicating the pathway is saturated at 100 
µM (Fig. 2.19). Despite the CHO-Gne and CHO-Gne/-Renbp cell lines producing less intracellular sialic acid 
following treatment with 1,3,4-O-Bu3ManNAc, these cell lines exhibited similar levels of azide 
incorporation following treatment with 1,3,4-O-Bu3ManNAz compared to the CHOWT and CHO-Renbp 
cell lines. This suggests that when treated with 1,3,4-O-Bu3ManNAz the CHO-Gne and CHO-Gne/-Renbp cell 
lines have a higher percent of their sialylation containing the azide moiety relative to CHOWT and CHO-
Renbp. These results provide preliminary evidence that knocking out Gne followed by treatment with 
ManNAc analogs can yield more homogenous glycoprofiles. Knocking out Renbp had minimal effect 
on sialic acid production levels relative to CHOWT and showed a similar MFI suggesting that azide 
incorporation levels are not different than the CHOWT line. Interestingly, incorporation of the azide 
analog decreased as analog concentration increased in all of the cell lines. This decrease may be 
attributed to the cytotoxicity of 1,3,4-O-Bu3ManNAz at higher concentrations (157). Furthermore, it 
appears that incorporation of the azide analog into cellular glycosylation saturates at or before a 





Figure 2.18 Representative flow cytometry data for CHOWT, CHO-Gne, CHO-Renbp, and CHO-Gne/-Renbp cells 
treated with 1,3,4-O-Bu3ManNAz. (A) Histogram overlays for each cell line treated with 0 µM, 100 µM, 200 
µM, or 300 µM of 1,3,4-O-Bu3ManNAz. (B) Histogram overlays for each cell line at each of the 1,3,4-O-







Figure 2.19 Flow cytometry mean fluorescence intensity of CHOWT, CHO-Gne, CHO-Renbp, and CHO-Gne/-Renbp 
cells treated with 1,3,4-O-Bu3ManNAz grouped by analog concentration (A) and cell line (B). Each cell 
line was treated with 0 µM, 100 µM, 200 µM, or 300 µM of 1,3,4-O-Bu3ManNAz, surface-labeled with DBCO-Cy5, 
and Cy5 fluorescence levels were measured using flow cytometry. The azide incorporation flow cytometry 





2.5.8 Azide Incorporation Plate Reading Assay 
The level of azide incorporation for each cell line was also measured using a plate reading assay. 
Again, each cell line was treated with 0 – 300 µM of 1,3,4-O-Bu3ManNAz and reacted with DBCO-Cy5 
which was then quantified using a fluorescence plate reader (Fig. 2.20). For each cell line the plate 
reading data exhibited a more pronounced decrease in MFI as concentration of 1,3,4-O-Bu3ManNAz 
increased, but in general followed the same overall trends as the flow cytometry data. Again, both the 
CHO-Gne and CHO-Gne/Renbp cell lines showed similar MFI levels as the wild type cells despite producing 
less free intracellular sialic acid. This supports the conclusion that knocking out Gne leads to a higher 
percent of cell surface glycans containing the azide moiety. Interestingly, the CHO-Renbp and CHO-Gne/-
Renbp cell lines yielded a measurably higher (although not significantly different) MFI at 100 and 200 
µM relative to the CHO-Gne and CHO-Renbp. Furthermore, this trend was also observed in the flow 
cytometry data, albeit to a smaller extent. This pattern may be due to knocking out Renbp which 
would further limit endogenous flow of ManNAc into the SABP leading to increased usage of the 
exogenously supplied 1,3,4-O-Bu3ManNAz analog. Alternatively, this may simply be due to random 
fluctuation within the assay itself. Previous work (157) and the reduction in MFI at higher 
concentrations (i.e. 200 and 300 µM) suggests that the non-natural azide analog is cytotoxic above 





Figure 2.20 Plate reading mean fluorescence intensity of CHOWT, CHO-Gne, CHO-Renbp, and CHO-Gne/-Renbp 
cells treated with 1,3,4-O-Bu3ManNAz grouped by analog concentration (A) and cell line (B). Each cell 
line was treated with 0 µM, 100 µM, 200 µM, or 300 µM of 1,3,4-O-Bu3ManNAz and reacted with DBCO-Cy5. 
Cy5 fluorescence levels were measure for all cells in each well and MFI measurements were adjusted based on 





2.5.9 Live-Cell Imaging of Azide-Labeled Glycans  
To further corroborate the flow cytometry and plate reading azide incorporation data the 
engineered cell lines were treated with Alexa fluor 488 conjugated to DBCO and imaged using 
fluorescence microscopy (Fig. 2.21). The images verify that all cell lines incorporated the 1,3,4-O-
Bu3ManNAz metabolites into cell surface glycans. There was negligible fluorescence in the control 
cell lines treated with ethanol. The basal fluorescence levels in untreated cells is consistent with the 
autofluorescence of mammalian cells or to random uptake of AF-DBCO into the cell membrane 
because it is nonpolar. Qualitatively, fluorescence appears to be highest for the 100 µM and 200 µM 
groups. The decrease could be due to the relative cytotoxicity of the analog at higher concentrations 
which would reduce the overall fluorescence in the image (157). There were not obvious differences 
in labeling observed when comparing the flow cytometry and fluorescent microscopy data, providing 
independent evidence that Gne knockdown increases the proportion of azide-labeled sialic acids in 





Figure 2.21 Representative fluorescence microscopy images of CHOWT, CHO-Gne, CHO-Renbp, and CHO-
Gne/-Renbp cells treated with varying concentrations of 1,3,4-O-Bu3ManNAz. Twenty-four hours after 
treatment with 1,3,4-O-Bu3ManNAz all samples were treated with AF-DBCO and imaged using an EVOS FL 
Imaging System. Live-cell imaging was performed in biological triplicate. Scale bars represent 200 µm.  
 
 
2.6 Concluding Remarks 
The goal of this project was to develop and implement a combined genetic engineering and MGE 
strategy to gain enhanced control over the magnitude and type of sialylation produced by CHO cells. 
To achieve this aim Gne and Renbp were targeted for CRISPR-Cas knockout to eliminate the primary 
and secondary routes by which ManNAc is introduced into the SABP. Gne was successfully knocked 




genomic analysis indicated indel generation but protein level analysis suggested the protein was still 
present.  
MGE technology was applied to these engineered cell line to modulate sialylation quantity and to 
introduce non-natural chemical groups onto sialic acid. When treated with 1,3,4-O-Bu3ManNAc each 
cell line produced more free intracellular sialic acid in a concentration dependent manner, however 
the Gne knockout CHO cells produced significantly less sialic acid. This supports the idea that Gne is 
the primary route by which ManNAc can enter the SABP and shows that nonspecific kinases must 
exist that can phosphorylate ManNAc in the absence of Gne. When each cell line was treated with 
1,3,4-O-Bu3ManNAz azide incorporation onto cell surface glycosylation was similar for all cell lines 
even the Gne knockout CHO cells. This strongly suggests that the for Gne knockout cells the 
proportion of surface sialic acids containing the azide moiety was higher compared to wild type CHO 
cells.  
Overall these results demonstrate that reducing endogenous ManNAc flux into the SABP via Gne 
knockout enhances the ability of MGE to control the composition of sialylation. The system could be 
extremely useful for creating cells and glycoprotein therapeutics with more controllable and 
homogenized glycoprofiles. Furthermore, this strategy can increase the percent of surface sialic acids 
containing non-natural chemical groups which could be a powerful tool for developing novel ADCs 
with better antibody to drug ratios.  
2.7 Future Directions 
This project yielded many interesting results and like most research has generated more 
questions than answers. The final section of this chapter discusses next steps for this project and 




2.7.1 Engineer CHO Cells with Validated Renbp Knockout 
Genomic and protein level analysis of Renbp knockout CHO cells gave conflicting results 
regarding whether Renbp had been successfully knocked out. Before any definitive conclusions can 
be made about how knocking out Renbp in CHO cells impacts sialylation this knockout needs to be 
fully validated. As a first measure the genomic and protein level analysis could be repeated to verify 
the results obtained in this study are accurate.  The western blot could also be tested with positive 
and negative control cell lines to verify the antibody is indeed binding Renbp. If these analyses are 
still in disagreement the presence of Renbp could be assessed at the mRNA level by performing qRT-
PCR experiments. If these experiments fail to provide a consensus regarding whether Renbp is truly 
knocked out it would be necessary to reengineer CHO cells using a different set of gRNA.  
2.7.2 Corroborate Periodate Resorcinol Assay Data  
These studies indicated that the CHO-Gne and CHO-Gne/-Renbp cells produced less intracellular free 
sialic acid relative to the CHOWT and CHO-Renbp cells when treated with 1,3,4-O-Bu3ManNAc. This data 
could be corroborated by performing Maackia amurensis or Limax flavus lectin blot analysis to 
determine if changes in free sialic acid manifest as changes in glycoprotein sialylation levels. Also, 
changes in surface glycosylation following 1,3,4-O-Bu3ManNAc treatment could be determined 
through Maackia amurensis or Limax flavus lectin flow cytometry experiments. These experiments 
should be repeated using the 1,3,4-O-Bu3ManNAz analog to determine if the same or similar changes 
in sialyation are observed with a non-natural analog.  
2.7.3 Measure Azide Incorporation at Lower 1,3,4-O-Bu3ManNAz Concentrations  
These studies measured the level of azide incorporation into cell surface glycosylation following 
treatment with 100, 200, and 300 µM 1,3,4-O-Bu3ManNAz. These experiments determined analog 
incorporation was highest at 100 µM with higher concentrations showing reduced incorporation. 




cytotoxicity of 1,3,4-O-Bu3ManNAz at concentrations exceeding 100 µM. While these studies 
indicated azide incorporation was highest at 100 µM it is possible incorporation could be higher at 
lower concentrations or between 100 and 200 µM. For this reason the flow cytometry, plate reading, 
and live-cell imaging experiments should be repeated but for 1,3,4-O-Bu3ManNAz concentrations 
between 0 – 150 µM. This would reveal the optimal analog concentration for maximum azide 
incorporation and indicate if the proportion of azide incorporation is titratable.   
2.7.4 Knockout Sialic Acid Lyase 
As previously mentioned (2.3 Specific Aims), ManNAc is endogenously fluxed into the SABP by 
three different enzymes: Gne, Renbp, and sialic acid lyase. This project aimed to knockout Gne and 
Renbp but did not consider eliminating sialic acid lyase. A natural extension and further optimization 
of this study would be to utilize CRISPR-Cas to knockout sialic acid lyase in order to obtain a CHO cell 
line with all possible endogenous routes for ManNAc to enter the SABP eliminated. In theory, this 
could further augment the ability of MGE technology to control protein sialylation levels and 




Chapter 3: Developing Recombinant Factor IX with an Extended 
Serum Half-life 
3.1 Overview 
The third chapter provides a description of a secondary project pursued for this thesis project 
including rationale for the project, methods, results, and discussion of the current state of the project. 
The overarching goal of this project was to create coagulation FIX with a prolonged serum half-life. 
This chapter begins with some brief background information which is followed by the specific aims, 
methods used, results, and a discussion on the current status of the project. 
3.2 Background  
This section briefly covers background information relevant to this chapter that was not 
extensively covered in the introduction. This section begins by describing hemophilia and FIX with 
an emphasis on how glycosylation, specifically sialic acid, can improve the pharmacokinetic 
properties of FIX. This is followed by a description of sialyltransferases and how they dictate the 
orientation sialic acid is added to a glycoprotein. Finally, this section explains how MGE technology 
could be utilized to increase FIX sialylation to improve serum half-life.  
3.2.1 Hemophilia and Factor IX 
Hemophilia is an inherited genetic bleeding disorder resulting from deficiencies in coagulation 
factors. There are two types of hemophilia; hemophilia A (deficiency in Factor VIII) is more common 
with an incidence rate of 1 in 5,000 male births, while hemophilia B (deficiency in FIX) has an 
incidence rate of about 1 in 30,000 male births. Hemophilia is not predisposed to any ethic group or 
geographical location (208, 209). Hemophilia B is of particular interest because of the potential for 
glycosylation to improve the pharmacokinetic properties of its deficient coagulation factor, FIX 




FIX (sometimes called the Christmas factor) is a 57 kDa vitamin K-dependent glycoprotein with 
glycosylation contributing to approximately 17% of its molecular weight. In a healthy adult human, 
the average plasma concentration of FIX is 2.5 – 5 µg mL-1 and its serum half-life is just 24 hours. 
Currently, prophylactic treatment of hemophilia B requires intravenous injection one to four times a 
week with FIX. There are currently 10 different FIX products available worldwide split into two 
types: plasma-derived or recombinantly produced (208, 209). The requisite for frequent intravenous 
injection is burdensome to patients and contributes to the relatively high payer cost of treatment, 
with some studies estimating this to be $350,000 per year (208, 210).  Substantial efforts are being 
made to increase the serum half-life of recombinantly produced FIX to alleviate patient burden 
caused by continuous injection and reduce treatment cost to increase global availability. Three 
products currently on the market (ALPROLIX [Biogen Idec], IDELVION [CSL Behring] and REBINYN 
[Nova Nordisk]), have been shown to increase serum half-life between 2.5 – 5-fold (208). ALPROLIX 
is recombinant FIX fused to a Fc region of an IgG enabling the modified protein to evade degradation 
in similar fashion to how an Fc receptor protects IgG antibodies (208, 211). IDELVION is recombinant 
FIX fused to human albumin that extends the half-life of FIX through pH-dependent binding of 
albumin to Fc receptors enabling the protein to avoid lysosomal degradation (212-216). REBINYN is 
a version of recombinant FIX that has been selectively PEGylated via GlycoPEGylation technology 
thereby prolonging serum half-life (208, 217).  
A relatively unexplored approach to augment recombinant FIX is to modify its glycosylation to 
prolong serum-half life. Previous research has shown that enzymatic removal of N-glycans increases 
the rate of catabolism of FIX and as described earlier N-glycan sialylation is known to improve serum 
half-life of recombinant glycoproteins including FIX (218-221). One study engineered additional N-
glycosylation sites into FIX and found that one hyperglycosylated FIX variant had a 2.4-fold higher 
serum half-life and a 5.4-fold reduction in clearance rate in mice relative to wild type FIX (221). 




identified three variants that exhibited a 2.4-fold higher serum half-life and a 4.5-fold reduction in 
clearance rate in mice relative to wild type FIX (222). Collectively, this work shows that modulating 
glycosylation can be an efficacious strategy for developing versions of FIX with improved 
pharmacokinetic properties.  
3.2.2 Sialyltransferases 
Sialyltransferases are a family of enzymes responsible for catalyzing the transfer of sialic acid 
from its activated nucleotide sugar donor, CMP, to an acceptor substrate which in most cases is a 
galactose, GalNAc, or sialic acid residue. In humans, sialic acid can be added to an acceptor substrate 
in three different orientations (2,3), (2,6), or less commonly (2,8). To accommodate the diversity 
stemming from different glyosidic linkages and acceptor substrates humans produce 20 different 
sialyltransferases split into four main classes: (i) -galactoside (2,3)-sialyltransferases (ST3GAL I-
IV), (ii) -galactoside (2,6)-sialyltransferases (ST6GAL I-II), (iii) GalNAc (2,6) sialyltransferases 
(ST6GALNAC I-VI), and (iv) (2,8)-sialyltransferases (44, 45).  
CHO cells produce glycosylation similar to human cells, but as discussed in section 1.3.1.4 
Chinese Hamster Ovary Cells subtle yet important differences exist between human and CHO 
glycosylation. Of particular importance for this chapter the St6gal1 gene in CHO cells is inactive 
meaning CHO cells are unable to add sialic acid to acceptor substrates in an (2,6) orientation (1). To 
circumvent this issue and “humanize” CHO cells sialylation it is common to engineer CHO cells to 
express the human ST6GAL1 (1.3.2 Genetic Glycoegineering) enabling CHO cells to produce both 
(2,3)- and (2,6)-sialylation. As an added benefit expression of ST6GAL1 has been shown to 
increase glycoprotein sialylation which can be extremely beneficial for biopharmaceuticals 
pharmacokinetic properties (112, 118-120, 122). Overexpressing St6gal1 increases sialyltransferase 
levels thereby increasing the capacity of a cell to sialylate glycoproteins. This enhanced capacity 




wild type CHO cells.  This has been demonstrated by studies showing that ST6GAL1 overexpression 
and MGE act synergistically to increase sialyation. Specifically, multiple studies have shown 
concomitant overexpression of ST6GAL1 and supplementation with 1,3,4-O-Bu3ManNAc can 
increase both free intracellular sialylation and glycoprotein sialylation, including for EPO and IgG 
(159-161). 
3.3 Specific Aims 
The overall goal of this project is to demonstrate that our lab’s 1,3,4-O-Bu3ManNAc analog can be 
used to increase sialylation of glycoproteins from CHO cells expressing ST6GAL1 thereby leading to 
an extended serum half-life for the target protein. A recent collaboration between our group and 
Michael Betenbaugh’s group demonstrated that treating CHO-K1 cells with 1,3,4-O-Bu3ManNAc can 
increase recombinant EPO sialylation levels by ~40% (159). To build on this work and demonstrate 
the broad applicability of this technology for numerous proteins this project aimed to test if 1,3,4-O-
Bu3ManNAc can be used increase sialylation of FIX recombinantly produced in CHO cells expressing 
ST6GAL1.  
Aim 1: Engineer a CHO-K1 cell line that expresses both ST6GAL1 and FIX. Preconstructed 
lentiviral particles were utilized to transduce CHO cells to insert the ST6GAL1 and FIX genes. 
Monoclonal cell populations were isolated via FACS and target protein expression was verified.  
Aim 2: Purify and characterize active FIX. Factor IX will be purified via immunoprecipitation 
and active forms will be isolated using fast protein liquid chromatography (FPLC). Factor IX 
activity will be verified using a fluorometric assay based on the ability of FIX to generate Factor 
X.  
Aim 3: Determine how supplementation with 1,3,4-O-Bu3ManNAc effects FIX sialylation 
levels. The engineered CHO cells will be supplemented with varying concentrations of 1,3,4-O-




3.4 Materials & Methods 
3.4.1 Cell Culture 
The CHO-K1 cell line (ATCC, CCL-61) was used for all cell engineering and experiments 
performed in this chapter. The CHO-K1 cell line is a subclone of the parental CHO cell line derived by 
Puck et al. from a biopsy of an ovary of an adult C. griseus (Chinese hamster) (193). Unless stated 
otherwise CHO-K1 cells were cultured in an adherent monolayer in F-12K nutrient mixture (Kaighn’s 
modification) (Corning, 10-025-CV) supplemented with 10% (v/v) heat inactivated, sterile filtered 
FBS, 1% (v/v) antibiotic-antimycotic solution (100x) (Sigma Aldrich, A5955-100ML), and 5% CO2 in 
a humidified environment at 37 °C. CHO-K1 cells were kept at or below 1 x 105 cells cm-2 to prevent 
them from reaching a confluent and quiescent growth stage. The cells were passaged every three to 
four days by aspirating the spent media, washing once with phosphate buffered saline (PBS) (pH = 
7.4), detached using 0.25% trypsin-EDTA (Gibco, 25200-056), and incubated in a 5% CO2, humidified 
37 °C environment for 5 to 10 minutes. After incubation, cell detachment was verified using a 
microscope and fresh complete F-12K media was used to transfer cells to a conical tube. Cells were 
pelleted via centrifugation for 5 minutes at 1057 x g, resuspended in 5 mL of complete F-12K media 
and seeded at a density of 1 x 104 cells cm-2. Cell density was determined using a Beck Z2TM Coulter 
Particle Count and Size Analyzer (Beckman-Coulter) with a 100 µm aperture, dilution factor of 1:101, 
and boundaries set between 7 and 25 µm. To measurements were made per sample and averaged to 
determine cell density. Wild type and all engineered CHO-K1 cells were cryopreserved using the 
same procedure outlined in section 2.4.2 Mammalian Cell Cryopreservation and thawed using the 
procedure described in section 2.4.3 Thawing Cryopreserved Cells.  
3.4.3 Lentiviral Transduction 
Twenty-four hours before transduction CHO-K1 cells were seeded at a density of 1.5 x 105 cells 




antimycotic solution. For the transduction, total transducing units (TU) was calculated using 
Equation 3.1 with different multiplicity of infections (MOI) (the number of transducing lentiviral 
particles per cell) ranging from 0.25 to 2. Then the total volume (mL) of lentiviral particles to be 
added to each well was calculated using Equation 3.2. Twenty-four hours after seeding the cells from 
two wells were detached, pelleted and counted (3.4.1 Cell Culture). The cell density from these wells 
was assumed to be approximately equivalent to the remaining wells and used to calculate TU. The 
media was aspirated from the remaining wells, the cells were washed once with PBS, and 1.5 mL of 
fresh culture media was added to each well. The calculated volume of CD75(ST6GAL1) (NM_173216) 
Human Tagged ORF Clone Lentiviral Particle (Origene, RC203776L3V) or Factor IX(F9) 
(NM_000133) Human Tagged ORF Clone Lentiviral Particle (Origene, RC219065L4V), polybrene 
(final concentration 8 µg mL-1), and culture media (to a final volume of 500 µL) were added to the 
appropriate well. The transduced cells were incubated for 18-20 hours with 5% CO2 in a humidified 
environment at 37 ° C. The ST6GAL1 lentiviral particle contains a Myc-DDK tag and the puromycin 
selection gene, while the Factor IX lentiviral particle contains a GFP tag and the puromycin selection 
gene.  
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3.4.4 Puromycin Selection 
CHO-K1 cells were seeded at a density of 1.5 x 105 cells mL-1 in 6-well plates with F-12K media 
supplemented with 10% (v/v) FBS and 1% (v/v) antibiotic-antimycotic solution. Twenty-four hours 




puromycin kill curve. Based on the puromycin kill curve data the optimal dose of puromycin was 
determined to be 8 µg mL-1.  
Twenty-four hours after transducing the CHO cells with the ST6GAL1 lentiviral particles the 
media was replaced with fresh F-12K media supplemented with 10% (v/v) FBS and 1% (v/v) 
antibiotic-antimycotic solution. Forty-eight hours post-transduction the CHO cells were treated with 
8 µg mL-1 of puromycin to select successfully transduced cells. The puromycin was replaced every 
third day for a total of 15 days at which point the cells were harvested for sorting and downstream 
analysis.  
3.4.5 Fluorescent Activated Cell Sorting  
Twenty-four hours after transducing the CHO cells with the FIX lentiviral particles the media was 
replaced with fresh F-12K media supplemented with 10% (v/v) FBS and 1% (v/v) antibiotic-
antimycotic solution. Forty-eight hours after transducing the CHO cells with the FIX lentiviral 
particles were detached and pelleted as described in section 3.4.1 Cell Culture. In contrast, the CHO 
cells transduced with ST6GAL1 lentiviral particles were detached and pelleted after selecting with 
puromycin for a 15 day period (3.4.4 Puromycin Selection). The pelleted cells were resuspended 
in 2% (w/v) BSA in HBSS to prevent cell aggregation during the sorting process. All FACS 
experiments were performed with the assistance of Hao Zhang in the Johns Hopkins Bloomberg 
School of Public Health Flow Cytometry and Immunology Core facility. Each sample was filtered with 
a sterile 35 µm nylon mesh strainer and combined with 10 µg mL-1 of PI. The samples transduced 
with FIX lentiviral particles were sorted based on the following parameters: morphology, granularity, 
PI negative, and GFP positive. While the samples transduced with ST6GAL1 lentiviral particles were 
sorted based on the following parameters: morphology, granularity and PI negative. Single sorted 
cells were then seeded in 96-well plates with 100 µL of F-12K media supplemented with 10% (v/v) 




monoclonal cell lines were supplemented with 50 µL of media every three days for a total of 12-14 
days. Monoclonal cell lines exhibiting positive growth were expanded to 6-well plates for 
downstream analysis and protein expression validation.  
3.4.6 Western Blotting 
Approximately 1 x 106 cells were harvested, transferred to a microcentrifuge tube, washed once 
with PBS, and resuspended in 10 – 25 µL of RIPA with protease inhibitor cocktail (Sigma Aldrich, 
P8340-5ml). The samples were incubated on ice for 30 minutes and each sample was vortexed every 
10 minutes to promote cell lysis. The samples were centrifuged at ~22,000 x g at 4 °C for 15 minutes 
and the resulting supernatant was transferred to a fresh microcentrifuge tube. Each protein sample 
was quantified via the BCA Assay (2.4.13 Western Blotting).   
Fifteen micrograms of each protein sample was combined with 4x laemmli concentrate with 2-
mercaptoethanol and diluted to 30 µL with RIPA buffer and protease inhibitor cocktail solution. The 
samples were denatured by heating at 90 °C for 10 minutes and loaded onto a Mini-PROTEAN TGX 
4-15% gradient gel with a 10-well comb and 30 µL well volume. The gel was run in 1x 
tris/glycine/SDS buffer (Biorad, 161-0772) for ~60 minutes at 100 volts. The protein was 
subsequently transferred to a 0.45 µM nitrocellulose membrane using standard wet transfer 
techniques with all components being equilibrated with 1x tris/glycine buffer (Biorad, 161-0771) 
with 20% (v/v) methanol. The transfer was run in 1x tris/glycine buffer (Biorad, 161-0771) with 
20% (v/v) methanol on ice at exactly 100 volts for 60 minutes. The membrane was blocked in 5% 
(w/v) BSA in TBST at room temperature for 60 minutes with agitation. The primary antibodies were 
diluted in 5% (w/v) BSA in TBST to the recommended concentration and added to the blot for 
overnight incubation at 4 °C with agitation. The primary antibodies used for western blots in this 
chapter and their dilution ratios are listed in Table 3.1. The next day the blot wash washed three 




(anti-mouse IgG, [Cell Signaling, 7076] or anti-rabbit IgG, [Cell Signaling, 7074]) was diluted in 5% 
(w/v) BSA in TBST at a 1:10,000 ratio, added to the blot, and incubated for 60 minutes at room 
temperature with agitation. After incubation the blot was washed three times with TBST for 10 
minutes each with agitation. While washing, the enhanced chemiluminescent substrate was prepared 
by combine SuperSignal West Pico PLUS Luminol/Enhancer solution (Thermo Fisher Scientific, 
1863098) with SuperSignal West Pico PLUS Stable Peroxidase solution (Thermo Fisher Scientific, 
1863099) in a 1:1 ratio. After the third TBST wash, the blot was incubated with the enhanced 
chemiluminescent substrate for ~30 seconds and transferred to a plastic sheet protector in a film 
cassette for imaging using Blu-C autoradiography films (Stellar Scientific, BLC-810-100).  
After imaging the blot was stripped for 15 minutes using Gentle Review Stripping Buffer 
(Amresco, A611-N552-13), washed three times with TBST for 10 minutes each and reblocked with 
5% (w/v) BSA in TBST for 60 minutes at room temperature with agitation. As a loading control, 
 actin (Cell Signaling, 3700) diluted in 5% (w/v) BSA in TBST at a 1:10,000 ratio was added to the 
blot and incubated at room temperature for 30 minutes with agitation. The blot was washed three 
times with TBST for 10 minutes each and HRP-linked Anti-mouse IgG diluted 1:10,000 in 5% BSA in 
TBST was added to the blot for 30 minutes. The blot was washed three times with TBST for 10 
minutes and imaged via autoradiography as described above. Western blot analysis was performed 
in triplicate to verify expression of ST6GAL1 and FIX.  
Table 3.1 Primary antibodies used to verify ST6GAL1 and FIX protein expression.  









0.44 µg mL-1 
(1:1000) 
Factor IX Antibody 
(B-3) 





3.4.7 Sambucus nigra Lectin Blot  
Approximately 1 x 106 CHO+ST6GAL1 cells were harvested, transferred to a microcentrifuge tube, 
washed once with PBS, and resuspended in 10 – 25 µL of RIPA with protease inhibitor cocktail (Sigma 
Aldrich, P8340-5ml). The samples were incubated on ice for 30 minutes and each sample was 
vortexed every 10 minutes to promote cell lysis. The samples were centrifuged at ~22,000 x g at 4 °C 
for 15 minutes and the resulting supernatant was transferred to a fresh microcentrifuge tube. Each 
protein sample was quantified via the BCA assay (2.4.13 Western Blotting). 
Five micrograms of each protein sample was combined with 4x Laemmli concentrate with 2-
mercaptoethanol and diluted to 30 µL with RIPA buffer and protease inhibitor cocktail solution. The 
samples were denatured by heating at 90 °C for 10 minutes and loaded onto a Mini-PROTEAN TGX 
4-15% gradient gel with a 10-well comb and 30 µL well volume. The gel was run in 1x 
tris/glycine/SDS buffer (Biorad, 161-0772) for ~60 minutes at 100 volts. The protein was 
subsequently transferred to 0.45 µm polyvinylidene difluoride membrane preequilibrated in 
methanol using standard wet transfer techniques with all other components being equilibrated with 
1x tris/glycine buffer (Biorad, 161-0771) with 20% (v/v) methanol. The transfer was run in 1x 
tris/glycine buffer (Biorad, 161-0771) with 20% (v/v) methanol on ice at exactly 100 volts for 60 
minutes. The membrane was blocked with 3% BSA in PBS with 0.1% (v/v) Tween 20 (PBST) at room 
temperature for 60 minutes with agitation. Biotin conjugated Sambucus nigra (SNA) lectin (B-1305, 
Vector Laboratories) lectin was diluted in PBST to a concentration of 1 µg mL-1 and added to the blot 
for 1 hour at 4 °C with agitation. After incubation, the blot was washed five times with PBST for 10 
minutes each. Streptavidin-HRP (Cell Signaling, 3999S) diluted in PBST at a ratio of 1:100,000 and 
added to the blot for 30 minutes with agitation. After incubation, the blot was washed five times with 
PBST for 10 minutes each. While washing, the enhanced chemiluminescent substrate was prepared 
by combine SuperSignal West Pico PLUS Luminol/Enhancer solution (Thermo Fisher Scientific, 




1863099) in a 1:1 ratio. After the last PBST wash, the blot was incubated with the enhanced 
chemiluminescent substrate for ~30 seconds and transferred to a plastic sheet protector in a film 
cassette for imaging using Blu-C autoradiography films (Stellar Scientific, BLC-810-100). 
After imaging, the blot was washed once with PBST and an inhibitory sugar solution comprised 
of 150 mM sialic acid and 150 mM lactose was added for 60 minutes with agitation. The inhibitory 
sugar solution serves as a negative control to verify the lectin is specifically binding to the target 
glycan motif. After incubating with the inhibitory sugar solution the blot was washed five times with 
PBST and incubated with streptavidin-HRP (1:100,000) in PBST. The blot was washed five times with 
PBST for 10 minutes each and imaged exactly as described above for the lectin. The inhibitory sugars 
should out compete the glycoproteins for lectin binding resulting in no signal when imaging. After 
imaging, the blot was probed with  actin (Cell Signaling, 3700) as a loading control (3.4.6 Western 
Blotting). After imaging the loading control, the blot was washed once with PBST for 10 minutes and 
amido black stain solution diluted in deionized water was added for one minute. The blot was 
destained for 30 minutes using 35% (v/v) 2-propanol, 10% (v/v) acetic acid solution. The blot was 
air dried for 30 minutes and imaged for another loading control measure. SNA lectin blots were 
performed in biological triplicate.  
3.4.8 Adapting CHO-K1 Cells to Serum Free Suspension Culture 
Once a monoclonal population of CHO-K1 cells expressing FIX and ST6GAL1 was engineered and 
validated the cells were sequentially adapted to serum-free, chemically defined suspension culture 
conditions. The engineered cells were detached and pelleted as described in section 3.4.1 Cell 
Culture. The cells were resuspended in FreeStyle CHO Expression Medium (Thermo Fisher Scientific, 
12651014) supplemented with 5% (v/v) FBS, 0.2% (v/v) penicillin streptomycin solution, 8 mM L-
glutamine, and 1x Pluronic F-68 (Gibco, 24040032). Cell density was determined using a Beck Z2TM 




vented shaker flask at a density of 5 x 105 cells mL-1. The suspension culture was incubated in a 
humidified environment at 37 °C with 5% CO2 at 125 rpm. Cell density and viability was monitored 
every day to establish growth rates of suspension culture. The media was changed every four days 
and once the culture reached a density of 1 x 106 cells mL-1 the cells were passaged to a new shaker 
flask at a density of 5 x 105 cells mL-1 with half the volume of FBS. This process was repeated until 
reaching 0.0156% (v/v) FBS at which point the cells were passaged to completely serum free media. 
Once the suspension culture reached a density of 1 x 106 cells mL-1 with at least 90% viability the 
cells were considered adapted and seeding density for all subsequent passages was reduced to 2.5 x 
105 cells mL-1.  
3.5 Results & Discussion  
3.5.1 Fluorescent Activated Cell Sorting  
CHO-K1 cells transduced with the ST6GAL1 lentiviral particles were selected with puromycin for 
15 days and single cells were sorted to isolate a monoclonal population. The ST6GAL1 transduced 
cells were gated based on multiple parameters to ensure viable, single cells were seeded. Cells with 
the correct morphology and size were selected by measuring FSC pulse height and SSC pulse height 
while granularity was accessed by measuring SSC pulse width and height and gating accordingly. At 
least 80% of the ST6GAL1 transduced CHO cells displayed the correct cellular morphology and 
greater than 90% of these cells were singlets. Finally, PI staining showed greater than 98% of the cell 
sample was viable (Fig. 3.1).  
Once a ST6GAL1 positive CHO cell line was established this cell line was transduced with a FIX 
lentiviral particle containing a GFP selection marker. The cells transduced with FIX were gated based 
on multiple parameters to ensure single, viable, GFP positive cells were selected. Over 90% of the cell 
sample displayed the appropriate cell morphology and approximately 89% were singlets. 




inefficient (Fig. 3.1). This is in contrast to a previous study that was able to achieve up to 95% 
transduction efficiency in CHO cells (223). These differences could result from not using the optimal 
MOI and cell density or from differences in the lentiviral plasmids and particles used.  
 
 
Figure 3.1 FACS data for sorting CHO cells transduced with ST6GAL1 and FIX lentiviral particles. All 
samples were sorted and gated based on morphology, granularity, and PI negative. (A) PI FACS histogram for 
CHOWT cells transduced with preconstructed ST6GAL1 lentiviral particles. (B) PI and GFP FACS histograms for 








3.5.2 Western Blotting  
Immunoblotting was used in order to verify ST6GAL1 expression in transduced CHO-K1 cells. 
Protein was extracted from monoclonal populations of CHO cells transduced with ST6GAL1 lentiviral 
particles and probed for expression using an ST6GAL1 polyclonal antibody (Thermo Fisher Scientific, 
PA5-27982) at a concentration of 0.44 µg mL-1. Approximately 30 monoclonal cell lines were 
screened with cell lines exhibiting a range of expression levels. From these cell lines a monoclonal 
population was selected that showed robust ST6GAL1 expression relative to CHOWT (Fig. 3.2) (Fig. 
3.3).  
Once a monoclonal population of CHO cells expressing ST6GAL1 was isolated these cells were 
transduced with FIX lentiviral particles. Again, following FACS, approximately 30 monoclonal cell 
lines were screened via western blotting with cell lines exhibiting a range of FIX expression levels. Of 
these cell lines one with high FIX expression (CHO+FIX/+ST6GAL1) was selected for downstream 
applications (Fig. 3.2). The observed molecular weight for FIX is typically around 50 kDa, however 









Figure 3.3 Representative western blot showing expression levels of FIX 
and ST6GAL1 in engineered CHO cells. Monoclonal populations of CHO cells 
transduced with FIX and/or ST6GAL1 lentiviral particles were isolated and 
probed for protein expression. Western blot analysis was performed in 
biological triplicate for each cell line.  
 
3.5.3 Sambucus nigra Lectin Blots 
SNA lectin blots were performed with the CHO+ST6GAL1 cell line in order to provide further 
evidence of ST6GAL1 expression. The CHO+ST6GAL1 sample yielded a stronger signal relative to the 
CHOWT protein sample, however the CHOWT sample still exhibited some basal signal levels (Fig. 3.3). 
The St6gal1 gene in wild type CHO cells is inactive meaning there should be not be any 2,6-linked 
sialic acid in CHOWT, however it has been shown that the SNA lectin also nonspecifically binds to 2,3-
linked sialic acid (122). Lectin specificity was demonstrated by incubating the blot in a 150 mM sialic 
acid and lactose solution. Overall the SNA lectin blot data provided further evidence showing the 





Figure 3.3 Representative SNA lectin blot comparing CHOWT and CHO+ST6GAL1 
2,6-linked sialic acid content. Five micrograms of protein for each sample was 
probed with 1 µg mL-1 of SNA lectin. Lectin specificity was demonstrated by adding 
an inhibitory sugar solution composed of 150 mM sialic and lactose. Equal loading 
was verified by amido black staining and probing for  actin. SNA lectin blots were 
performed in biological triplicate.  
 
3.6 Concluding Remark 
The goal of this project was to use MGE and genetic engineering to increase the serum half-life of 
FIX recombinantly produced by CHO cells. Lentiviral transductions were utilized to develop a CHO 
cell line co-expressing ST6GAL1 and FIX which was verified through immunoblotting. Expression of 
ST6GAL1 enables to CHO cells to add sialic acid to glycoproteins in the (2,6) orientation in addition 
to the (2,3) orientation as is found in humans. Expressing ST6GAL1 in CHO cells also has the added 
benefit of enhancing the effectiveness of MGE in increasing sialylation. In sum, this engineered cell 
line will provide a foundation for demonstrating MGE, specifically our group’s 1,3,4-O-Bu3ManNAc 




3.7 Future Directions  
While a CHO cell line expressing both ST6GAL1 and FIX was successfully created, the final two 
aims of this project were not completed. The final section of this chapter describes next steps to 
complete the remaining aims of this project. Additionally, this section highlights future studies that 
can be conducted using glycoengineered FIX. 
3.7.1 Purification and Activity Assay 
In order to determine if MGE can be used to increase sialylation of recombinantly produced FIX 
an effective purification process needs to be developed. Previous studies used a two-step approach 
to purify FIX consisting of an immunoaffinity step followed by anion exchange chromatography to 
isolate active fractions of FIX (217, 221, 222, 224-226). These studies can be used as a foundation for 
developing a successful purification process of FIX from CHO cells. After purifying FIX it will also be 
critical to verify the isolated coagulation factor is active. Multiple activity assays are commercially 
available which commonly measure FIX activity by measuring its ability to generate Factor X.  
3.7.2 Characterize Changes in Sialylation After MGE 
Once a FIX purification process has been developed and validated, MGE can be implemented to 
increase FIX sialylation. Specifically, the CHO cells producing FIX can be treated with 1,3,4-O-
Bu3ManNAc to increase flux through the SABP and in theory increase FIX sialylation. Changes in FIX 
(2,3)- and (2,6)-linked sialylation could be determined via Maackia amurensis and SNA lectin blots 
and mass spectrometry analysis.  
3.7.3 In vivo Assessment of Serum Half-Life 
If MGE technology is able to increase recombinantly produced FIX in vivo studies could be used 
to test if the glycoengineered FIX has a prolonged serum half-life. Serum half-life could be assessed 




FIX is conjugated to GFP, protein retention could also be analyzed using fluorescence microscopy to 
measure GFP levels. If MGE was able to increase FIX sialylation and serum half-life it would represent 
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